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ABSTRACT 
Monoamine oxidase-A (MAO-A) is an enzyme that has historically been linked to major 
depressive disorder (MDD). The prevalence of MDD among breast cancer patients is almost 
25%, but realistically it is underdiagnosed within this patient population. Most breast cancer is 
deemed estrogen receptor positive [ER(+)] and is commonly treated with the anti-estrogenic 
chemotherapeutic compound tamoxifen. Resistance to tamoxifen has been associated with a 
paradoxical activation of the stress-associated kinase, p38(MAPK) (normally associated with cell 
death). Our research group has recently demonstrated that p38(MAPK) can regulate the function 
of MAO-A in glial cells. Taken together, MAO-A, depression and p38(MAPK) are all associated 
with a poor prognosis in breast cancer patients, particularly those with an ER(+) status. Several 
mechanisms have been proposed in each respect and we hope to further elucidate this 
relationship by focussing on the interaction between MAO-A and p38(MAPK) in the context of 
breast cancer. 
The hypothesis states that a functional interaction between the p38(MAPK) and MAO-A 
systems alters breast cancer cells in an ER-dependent manner.  
The proposed objectives of this project are to determine what might be influencing 
MAO-A function in breast cancer cells, and how changes in MAO-A function affect cell 
phenotype. Using pharmacological approaches (i.e. antidepressant drugs), we investigated the 
role of MAO-A and p38(MAPK) on selected characteristics of ER(+) (e.g. MCF-7) and ER(-) 
(e.g. MDA-MB-231) breast cancer cells under four treatment conditions, which include 
clorgyline (CLG), an antidepressant MAO-A inhibitor, and SB203580, an inhibitor of 
p38(MAPK).  
Our results indicate that the very high MAO-A activity in MDA-MB-231 (MB-231) cells 
was partly dependent on p38(MAPK) activity. The tumourigenic properties (e.g. anchorage-
independent growth, migration) of MB-231 cells depended on both MAO-A and p38(MAPK) 
functions, although the effects were not additive suggesting that both inhibitors were exerting 
their respective effects via common signalling targets. The role of MAO-A and p38(MAPK) on 
MB-231 mitochondrial function and cell growth was negligible. In contrast, MAO-A and 
p38(MAPK) only influenced mitochondrial function in MCF-7 cells and did not affect any of the 
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other tumourigenic properties measured. Immunocytochemical methods, supported by Western 
blotting, revealed an increase in E-cadherin expression in both cell lines. This suggested that 
MAO-A and p38(MAPK) could be influencing transitions between epithelial and mesenchymal 
phenotypes. 
Our in vitro findings suggest that MAO-A and p38(MAPK) might contribute to a 
common mechanism in breast cancer cell lines, but that their influence on cell phenotype is less 
dependent on the respective cell's ER status and perhaps more so dependent on the cell's 
metastatic potential. If this is the case, then the contribution of MAO-A and p38(MAPK) to 
[clinical] metastatic breast cancer should be duly considered. Our ongoing investigations are 
focussing on the influence of clinically relevant antidepressants on breast cancer cell phenotype 
in vitro. 
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1.1 Major Depressive Disorder 
Mood disorders are among the most commonly identified mental illnesses (1). According 
to the Public Health Agency of Canada approximately 8% of adults will experience major 
depression within their lifetime (1). On an international scale, major depressive disorder (MDD) 
is considered to be the leading cause of ‘years lived with disability’ (1). Depression is recognized 
as a heterogeneous disorder with many different subtypes developing from a variety of etiologies 
(2, 3); however, the term ‘depression’ will be used throughout this document, with the 
understanding that any given context could encompass any or all subtypes. Clinical depression or 
major depressive disorder is a mood disorder in which a person will experience intense feelings 
of distress over an extended period of time resulting in hopelessness, insomnia, and an aversion 
to perform daily activities and engage in social interactions (4). Initial detection of depression by 
a primary care physician typically involves assessing answers given by the patient to a specific 
series of questions (5) that will normally indicate the need for a more detailed assessment. 
Further analysis may require the use of symptom-based rating scales and diagnostic criteria that 
is commonly extracted from the Diagnostic and Statistical Manual of Mental Disorders-Fourth 
Edition, Text Revision (DSM-IV-TR) (6). A number of specific symptoms must be observed 
before categorizing a condition as MDD in order to ensure proper treatment and ultimate 
recovery. The DSM-IV provides four categories of symptoms for diagnosis: affective, 
behavioural, cognitive, and somatic symptoms (6). Frequently, studies will report patients as 
experiencing depressive symptoms which could include any number of signs, for example, 
feelings of helplessness (affective/mood), preferred isolation (behavioural), lack of focus 
(cognitive) and insomnia (somatic/physical) (7). At least one major depressive episode lasting 
two or more weeks, during which time a minimum of four depressive symptoms are displayed, 
qualifies for a diagnosis of MDD (8). Over half of those who have experienced only a single 
episode of major depression will suffer recurrence, thereby identifying a previous history of 
depression as a very strong predictor of future episodes (9).  
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Depression is not limited to a specific demographic; although it has been consistently 
documented that women experience depression at higher rates than men (10).  Within a lifetime, 
the onset of depression can reflect turning points within a typical life cycle and is quite common 
during adolescence and early adulthood (11). However, those over the age of 80 also experience 
depression at increased rates as a result of increased physical dysfunction, loss of independence, 
and social isolation (11). Research has yet to uncover the precise aetiology of the condition, but 
it is currently believed to be brought on by a combination of genetic factors and environmental 
triggers (12) that contribute to a chemical imbalance in the central nervous system (CNS) (13-
15).  
 
1.1.1 Depression and the Serotonin System 
MDD has long been associated with the serotonergic system, thus explaining the 
underlying action of several antidepressant medications (13, 16, 17). Serotonin (5-
hydroxytryptamine; 5-HT) is a mood-regulating hormone, which at reduced levels has been 
implicated in the onset of different psychopathological conditions (18). 5-HT is a tryptophan 
derivative best known for its role as a neurotransmitter (19). Interestingly, however, only 1% of 
5-HT is localized in the central nervous system (19); the remainder serves as an active hormone 
in the peripheral immune, circulatory, reproductive, and gastrointestinal systems (20). 
Nevertheless, various pharmaceutical agents have been designed to increase the availability of 
CNS 5-HT to provide relief of depressive symptoms. For instance, selective serotonin reuptake 
inhibitors (SSRIs) are frequently prescribed for the treatment of depression and inhibit 5-HT 
reuptake into the presynaptic neuron. This allows for an accumulation of 5-HT within the 
synaptic cleft and, thus, it is available to postsynaptic receptors (21). An alternative 
pharmacological approach led to the synthesis of agents which inhibit the metabolic action of 
enzymes that degrade 5-HT, such as monoamine oxidase (MAO) (22). 
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1.1.2 Monoamine oxidase  
In humans there are two functionally distinct forms of the MAO enzyme: MAO-A and 
MAO-B, which are both integral outer mitochondrial membrane proteins. Their dependence on a 
flavin co-factor for full activation places them in the family of flavoproteins (23, 24). The 
existence of multiple forms of the protein became generally accepted in 1971 (25) and it would 
only later be discovered that MAO-A and MAO-B are encoded by two separate genes (26), 
despite having a 70% amino acid sequence homology (27). The primary structure of these two 
distinct proteins consists of 526 (MAO-A) and 520 (MAO-B) amino acid residues with 
respective molecular weights of 59.7 kDa and 58.8 kDa (28). There are four highly conserved 
regions between the MAO isozymes (Figure 1); these include (1) an adenosine diphosphate 
(ADP)-binding site; (2) a substrate-binding domain; (3) a C-terminus region, which possibly 
forms the transmembrane domain; and (4) a covalent- flavin adenine dinucleotide (FAD) binding 
site (29). MAOs share no sequence similarity with other known proteins, with the exception of 
the ADP-binding sequence, which is typically present in other FAD-dependent enzymes (30). 
This region is predicted to fold into a βαβ conformation, forming a site for interaction with the 
ADP moiety of FAD (31). FAD is covalently linked to Cys406 in MAO-A and is a functional 
component of the overall substrate oxidation reaction (32). 
MAO-A and B also display differences in tissue distribution, structure and substrate 
preference. These isozymes are present in most mammalian tissue, but there are species-specific 
differences (33-35). In humans, both MAO-A and -B are expressed in most tissues with the 
exclusion of the blood platelets (which expresses MAO-B exclusively) (34).  MAO-A and MAO-
B are most abundant in the liver and placenta and have the lowest levels of expression in the 
spleen (35). The lungs, placenta and small intestines have higher MAO-A activity as opposed to 
the myocardium in which MAO-B is most active (35). The presence of MAO isozymes extend to 
many areas of the human brain. MAO-A is predominantly localized in catecholaminergic 
neurons whereas serotonergic neurons appear to contain MAO-B (36). 
Both enzymes catalyze the oxidation of diverse amines, including 5-HT, dopamine and 
epinephrine (37). However, whereas MAO-B has a greater affinity for the trace amine, 
phenethylamine, MAO-A is more selective and likely to degrade 5-HT, epinephrine and 
norepinephrine  (14, 33).  Binda and  colleagues  (38)  provide  a  concise  representation  of   the  






Figure 1. Human MAO-A structure. The ribbon diagram shows the flavin binding domain 
(blue), the substrate domain (red) and the C-terminus membrane binding domain (green). The 
covalent flavin moiety is shown in yellow as a ball and stick model (39). Reprinted from (39), 
with permission from Elsevier. 
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reaction catalyzed by MAOs. The researchers explain that the oxidative deamination reaction is 
initiated by the transfer of electrons from the amine nitrogen to oxygen coupled with the 
reduction of FAD to FADH. The resulting intermediate imine is spontaneously hydrolyzed to the 
corresponding aldehyde and ammonia. The cofactor is reoxidized by molecular oxygen, which 
itself is then reduced to hydrogen peroxide (H2O2) (33, 38, 40) (Figure 2). The H2O2 by-product 
of this reaction is a concern as it is a source of hydroxyl radicals, and thus contributes to 
oxidative stress (41, 42).  
 
1.1.3 MAO-A 
The primary role of MAO-A is to regulate the levels of aromatic monoamines in the 
central nervous system and peripheral organs (43).  As mentioned, this involves the degradation 
of biogenic amines including the classical neurotransmitter 5-HT (44). The interaction between 
MAO-A and classical neurotransmitters has led to the extensive study of the enzyme in the 
context of several neurological conditions, including MDD (36). This has resulted in the 
development of MAO-Inhibitors (MAOIs), most relevant to this discussion are a class of 
antidepressants that target MAO-A to allow for an increase in 5-HT availability (45).  
 
1.1.4 MAOIs: Clorgyline 
MAOIs were the first class of drugs to demonstrate true antidepressant effects (46) and 
clorgyline was among the first acetylenic inhibitors of monoamine oxidase to be synthesized 
(47). Clorgyline [N-methyl-N-propargyl-3-(2,4-dichlorophenoxy) propylamine] is a 
propargylamine compound that selectively binds to MAO-A resulting in irreversible inactivation 
(48) and the subsequent rise in neurological monoamine concentrations, particularly the target 
substrate 5-HT (49).  Clorgyline covalently binds to MAO-A in the substrate binding site. The 
mechanism-based inhibition by this ‘suicide’ inhibitor occurs following the binding of clorgyline 
to the N(5) atom of the FAD cofactor, explains Finberg and colleagues (46). This binding 
triggers MAO-A to process clorgyline as if it were a substrate. A reactive intermediate forms 
covalent bonds within the FAD-binding domain and this blocks subsequent access by substrates,  










     RCH2NH2  +  FAD  +  H2O  +  H
+
     RCHO  +  FADH2  +  NH4
+ 
     FADH2  +  O2     FAD  +  H2O2 
 
 
Figure 2. The oxidation of amines by monoamine oxidases. The amine substrate is oxidized 
while FAD is reduced to FADH. The intermediate imine is then hydrolyzed resulting in an 
aldehyde, FADH2, and an amine. In the next phase of the reaction, FADH2 is oxidized back to 
FAD and oxygen is reduced to H2O2 (38).  
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thereby irreversibly inhibiting MAO function (50). This irreversibility underlies the use of the 
label ‘suicide’. 
 
1.2 Depression in Cancer Patients  
The interdependent relation of comorbid cancer and depression is receiving greater 
attention along with the adverse consequences of this interaction. The coexistence of depression 
in cancer patients is almost 40% (51, 52); however, incidence rates of depression vary 
considerably between the different forms of cancer (53). Pancreatic and oropharyngeal cancers 
are associated with a strikingly high incidence of clinical depression (54), but the factors 
responsible for this stronger association are unknown and may be attributed to a 
pathophysiological effect, adverse side effects of treatment or an as yet unidentified variable 
(53). Moreover, the scarcity of peer-reviewed studies, high rates of patient drop-out in clinical 
studies, and the low number of total patients analyzed in the past 30 years precludes arriving at 
any definitive inferences (55). Fann and colleagues (56) performed a literature review on the 
prevalence of depression in women with breast cancer in the last 20 years. This study confirmed 
that, with the exception of pancreatic and oropharyngeal cancers, breast cancer patients have the 
leading incidence of depression compared to all other forms of cancer (51, 56).  In an 
observational cohort study done out of London, England (57), over 200 female participants were 
assessed for depression in early-stage breast cancer. Almost 50% of the women experienced 
depression, anxiety or both in the first year following the initial diagnosis.  
Regardless of primary tumour site, depression is three times more common in cancer 
patients compared to those in the general population (55). Although depressive symptoms 
frequently manifest within the cancer patient population, depression continues to be 
underdiagnosed throughout this demographic and is overlooked for a variety of reasons (58). For 
instance, experiencing psychological distress is expected in those who have been diagnosed with 
a terminal illness, to a certain degree. Furthermore, the threshold separating appropriate sadness 
and depression is difficult to detect among cancer sufferers (59). It becomes a challenge to 
attribute the onset of somatic symptoms, for example, either to cancer and the associated 
treatments or to depression (60). This is understandably a difficult task; however, treating a 
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depressive illness in a cancer patient is critical and can yield substantial benefits including 
maintenance of a stronger immune system (61) and extension of overall survival (62). If left 
untreated, however, depressed cancer patients demonstrate reduced medical compliance (63), 
extended inpatient care (64), and a poorer quality of life (65) coupled with increased mortality 
rates (53). Bultz and Carlson (66) recognize the impact of psychological distress within a cancer 
setting and emphasize the importance of monitoring emotional affliction as closely as the 
attention given to traditional vital signs. As was alluded to, the benefits of timely treatment of the 
comorbidity has been well-documented and reiterated in several studies throughout the literature 
(66). In cancer patients, antidepressants and psychotherapeutic interventions are recognized as 
effective treatments for clinical depression (67). 
 
1.2.1 MAO-A in Cancer 
MAO-A has been historically implicated in depression; however, recent findings have 
now also implicated this enzyme in cancer (19, 68-70). In a comparative analysis of gene 
expression in multiple cancers among various species, Rybaczyk and colleagues (19) 
demonstrated a consistent decrease in MAO-A mRNA expression in 95.4% of human cancer 
patients compared to normal controls. In human breast tumours, the researchers report a 5.6 fold 
decrease in MAO-A compared to normal controls. Based on this, these authors and others 
propose MAO-A as a biomarker of cancer progression (19, 71). The literature, however, remains 
inconclusive regarding the involvement of 5-HT metabolism in carcinoigenesis (19). The role of 
5-HT in the context of cancer is ambiguous as a drug-induced rise in 5-HT may contribute to a 
protective mechanism in some forms of cancer (72, 73), whereas in vitro results propose that an 
increase in 5-HT appears to promote mitosis (74). Epidemiological studies have also supported 
an association between risk of cancer development and the use of antidepressants (75).  As a 
result of the downregulation of MAO-A mRNA observed in cancerous tissues, it is legitimate to 
question how MAOIs may contribute to cancer risk. Indeed, increased cell proliferation has been 
observed in animal models treated with MAOIs (76, 77); however, this effect of MAOIs has not 
been substantiated in humans (19).  
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1.3 Breast Cancer  
Breast cancer has become one of the most relevant cancers due to its incidence and 
mortality rates worldwide. Breast cancer has the highest incidence among females compared to 
all other cancers and is the second leading cause of death from cancer among women (78). 
Although breast cancer is one of the most common malignancies in women, 1% of all cases 
occur in men (79).  
Similar to most cancerous tumour cells, breast cancer cells exhibit unique characteristics 
that arise from genetic mutations and contribute to a pathological phenotype (80) involving 
uncontrolled rapid cell division and immortalization, which refers to the ability of tumour cells to 
grow indefinitely (81). The transformation from a normal cell type to a cancerous or neoplastic 
cell is attributed to a number of factors including, gene amplification (82), changes in membrane 
components, and reorganization of the cytoskeleton (83). This multistep process is generally 
referred to as tumourigenesis (84). During tumourigenesis, cancer cells acquire the ability to 
overcome growth-inhibitory signals and divide indefinitely in the absence of growth-stimulating 
signals undetected by the host immune responses (84). As the cancer cell continually replicates, 
oxygen and nutrient supplies are maintained through tumour angiogenesis (85). These events 
mark the formation of malignant tumors that develop in the breast tissue and can subsequently 
invade adjacent normal tissue and disseminate to distant sites (86).  
Malignant breast tumours are commonly differentiated based on estrogen receptor (ER) 
status, progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER2) 
status (87). This is a necessary assessment as it can provide critical information towards the 
selection of the most effective method of targeted adjuvant therapy, which can significantly 
impact overall prognosis. 
 
1.3.1 Estrogen Receptor Status 
Fifty to eighty percent of breast cancer cases are classified as ER-positive [ER(+)] (88), 
and of the treatments used against ER(+) breast cancer cells, tamoxifen is among the most widely 
prescribed drugs (89). Tamoxifen functions as a competitive inhibitor to hinder cell growth 
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stimulated by estrogen (90). There are two forms of the estrogen receptor that respond to 17β-
estradiol (estrogen), ERα and ERβ, the latter generally being less relevant to breast cancer (91). 
In breast tissue the main effect of estrogen is to cause cells to grow and divide, which occurs in 
epithelial cells lining mammary glands in preparation for lactation (92). This is a normal and 
beneficial function of estrogen but by triggering cell division in these cells, the risk of breast 
cancer development also increases (93). The mutations in genes that regulate cell division are not 
caused by the presence of estrogen. However, because estrogen stimulates proliferation, the cells 
with existing mutations will also proliferate and may acquire additional mutations in DNA to 
eventually become cancerous (94). In any case, regardless of whether mutated cells are present, 
the exposure to estrogen in normal cells creates a greater opportunity for genetic errors to occur 
during DNA replication. Furthermore, once a tumour develops the cancerous cells will continue 
to respond to estrogen-stimulated growth (95).  
The classic nuclear estrogen receptors, ERα and ERβ (96), bind to estrogen resulting in a 
conformational change to allow the complex to translocate to the nucleus and interact with DNA 
at specific sites known as estrogen response elements (97). This attachment initiates the binding 
of coactivator proteins resulting in the activation of genes, which will synthesize proteins that, in 
breast cells, will influence cell proliferation (98). This process is restricted by tamoxifen, which 




Tamoxifen is designed as a pro-drug, meaning that the compound is administered in an 
inactive form that is chemically transformed in vivo through metabolic processes in the liver to 
an active form (100). The conversion of tamoxifen to its active form by the cytochrome P450 
(CYP) system produces active metabolites such as 4-hydroxytamoxifen (101), which is an ER 
antagonist with a far greater binding affinity than tamoxifen. The ER/tamoxifen complex recruits 
co-repressor proteins to effectively inhibit the transcription of estrogen-responsive genes (102). 
The anti-estrogenic properties of this hormonal therapy force cells to arrest in the G0 and G1 
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phase of the cell cycle (103). Hence, tamoxifen does not destroy cells but prevents cell division 
and is therefore considered a cytostatic as opposed to a cytocidal substance (103). 
Tamoxifen is classified as a selective estrogen receptor modulator (SERM), meaning that 
it can selectively block or stimulate estrogen receptors depending on the target tissue (104). The 
structure of the estrogen receptor is slightly modified depending on the tissue in which it is 
located (105, 106). In breast cells the gene activation for specific growth-promoting proteins is 
blocked by tamoxifen. However, tamoxifen can mimic estrogen in other areas of the body, which 
can have both positive and negative outcomes (107). For instance, in the uterus, estrogen 
promotes cell proliferation and tamoxifen yields the same effects (108, 109). Similar to 
estrogen’s role in breast cancer development, tamoxifen can increase the risk of endometrial 
cancer (107). Thus, the complex properties of tamoxifen still require further investigation (108, 
109).  
Not all breast cancer cells express the estrogen receptor. These ER(-) breast cancers tend 
to be more aggressive and are not susceptible to the therapeutic effects of tamoxifen (110). 
Furthermore, in 10% of the general population the enzyme CYP2D6 (member of the cytochrome 
P450 super family) that converts tamoxifen to its active form is functionally impaired, thus 
preventing tamoxifen from providing maximum chemotherapeutic benefits (111). When 
considering tamoxifen as a potential treatment option, CYP2D6 enzyme function can be tested, 
but its metabolic abilities are also altered by certain medications. For instance, the activity of 
CYP2D6 is blocked in the presence of some commonly used antidepressants and antihistamines 
namely, SSRIs and diphenhydramine (Benadryl), respectively (112).  
 
1.3.3 Antidepressants and Tamoxifen 
As a pro-drug, tamoxifen is relatively inactive prior to hepatic metabolism by the 
CYP450 system (111). A number of metabolites are produced following primary and secondary 
metabolism; the most pharmacologically relevant of these products are 4-hydroxytamoxifen (4-
OH-TAM) as well as endoxifen (113). In the past tamoxifen’s anti-estrogenic action has been 
attributed to the increased potency of the 4-OH-TAM metabolite; however, more recent evidence 
has indicated endoxifen to be more  clinically  efficacious  in chronic  tamoxifen-treated  patients  
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(114).  Endoxifen is generated at the highest concentration following oxidation of tamoxifen’s 
most abundant metabolite, N-desmethyltamoxifen, by the CYP2D6 enzyme (114).  
Major antidepressants, such as the SSRIs fluoxetine and paroxetine, are potent CYP2D6 
inhibitors. These drugs directly affect endoxifen concentrations in patients treated with 
tamoxifen by converting moderate metabolizers into poor metabolizers (115). By acting as 
competitive inhibitors these antidepressants interrupt the biotransformation of tamoxifen into its 
active metabolites (Figure 3); thereby, significantly reducing the antineoplastic effects of this 
chemotherapeutic agent (103). Yet this does not hold true for all antidepressants. For example, 
venlafaxine is only a weak inhibitor of the CYP2D6 enzyme, and thus it has no significant effect 
on the cancer-preventing benefits of tamoxifen (116). 
 
1.3.4 Tamoxifen Resistance  
The ability of cancer cells to escape apoptosis is considered an essential “hallmark of 
cancer” (117). Laboratory and clinical investigations have implicated certain stress signalling 
pathways in de novo and acquired tamoxifen resistance. For instance, elevated levels of 
phosphorylated c-Jun N-terminal kinases (JNK) and activated p38(MAPK) are associated with 
the acquired resistance to tamoxifen (118). A suggested mechanism of resistance associated with 
activated p38(MAPK) has been described in endometrial adenocarcinoma cells. Lee and Bai 
(119) reported an increase in p38(MAPK) activity by both tamoxifen and estrogen, resulting in 
the inhibition of ER nuclear export, enhancement of ER-coactivator interactions, 
phosphorylation of the ER-α protein, and increases in the uterine-specific agonist activity of 
tamoxifen. Each of these events contributes to an overall enhancement of the growth-stimulating 
activity of estrogens in endometrial cancer.  
As mentioned, estrogen receptor expression is presently a defining feature of breast cancer and 
provides an efficient target for treatment. Estrogen has become associated with an increasing 
number of signalling pathways including both MAO-A (120) and p38(MAPK) (119, 121). The 
regulation of MAO-A is multifactorial and there is also evidence for the role of estrogen in this 
process (120). In a similar fashion to MAOIs, estrogen reduces MAO-A activity to raise levels of 
5-HT and  catecholamines in the brain  (122).  Estrogen-induced stimulation of cell  proliferation   







Figure 3. The effects of certain SSRIs on tamoxifen metabolism.  The metabolism of 
tamoxifen to its active metabolite, endoxifen, is dependent on the SSRI being administered 
(123).  Reprinted with permission. © (2008) American Society of Clinical Oncology. All rights 
reserved. 
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has long been a recognized factor in the development of breast cancer. Therefore, the influence 
of the regulation of MAO-A by estrogen could reveal a mechanism that can be applied to the 
understanding of tamoxifen resistance in breast cancer patients. 
An explanation for the development of tamoxifen resistance would consequently allow 
physicians to identify the patients most likely to benefit from tamoxifen treatment. Gutierrez and 
colleagues (124) conducted a study to investigate the molecular changes associated with 
tamoxifen-resistant breast cancer and concluded that the biological pathways influencing tumor 
growth are altered as the tumor continues to progress. These findings highlight the complexities 
involved in understanding tumourigenicity. Interestingly, the group also observed increased 
p38(MAPK) activity in tamoxifen-resistant tumour samples from both animal and human tissues. 
Studies have also documented that an increase in extracellular signal-regulated kinases (ERKs) 
and p38(MAPK) signalling hinders the anti-proliferative effect of tamoxifen (118, 124). In breast 
cancer patients receiving tamoxifen, elevated p38(MAPK) activity was predictive of a poor 
prognosis (118). Tamoxifen-resistant cells showed increased basal levels of total and 
phosphorylated p38(MAPK) and it was then demonstrated that blocking the effects of 
p38(MAPK) with the specific inhibitor SB203580 reduced cellular proliferation in MCF-7 cells 
regardless of the cells’ sensitivity status to tamoxifen (118). These studies consistently identify 




1.4.1 MAPK Family    
The mitogen-activated protein kinases (MAPKs) represent a family of highly conserved 
signal transducing enzymes that regulate cellular responses to various external stimuli (125). 
MAPKs consist of three major subgroups that selectively respond to upstream signalling events 
and independently perform an extensive range of functional roles (126) (4). Firstly, extracellular 
signal-regulated kinases (ERK) preferentially respond to growth factors to produce pro-survival 
signals and promote cell proliferation (127). The remaining two cascades interact significantly 








Figure 4.  Mitogen-Activated Protein Kinase (MAPK) cascades. Pathway diagram 
reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). 
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with each other and include the stress-associated kinases, JNK and p38(MAPK), which can 
promote inflammation and initiate apoptosis (126). Despite having different functions, these 
three classical signalling cascades undergo an equivalent activation mechanism whereby MAPK 
kinase (MAPKK) catalyzes the phosphorylation of both a Thr (Threonine) and a Tyr (Tyrosine) 
residue on its downstream targets (128). 
 
1.4.2 p38(MAPK) 
The p38(MAPK) cascade was first described in 1994 (129) and plays a critical role in 
cytokine production and the stress response (127). It is known to be activated by a variety of 
extracellular stressors including proinflammatory cytokines, osmotic shock, UV irradiation, 
bacterial lipopolysaccharides (LPS) and hydrogen peroxide induced oxidative stress (130).  As a 
result, p38(MAPK) can directly influence a range of cellular processes including cytokine 
production, transcriptional regulation, cytoskeletal reorganization and apoptosis (131). The dual 
phosphorylation of p38(MAPK)’s Thr180 and Tyr182  of the Thr-Gly-Tyr (TGY) tripeptide motif 
by MAPK kinase-3 or -6 (MKK3 and MKK6) leads to the rapid activation of the enzyme (132); 
otherwise, p38(MAPK) is relatively inactive in its non-phosphorylated form (129). There exists 
four isoforms of p38(MAPK), α, β, γ and δ, each with differential tissue expression (133). The 
p38(MAPK)-α and -β isoforms are expressed in a wide variety of tissues in the body (134) 
whereas the γ and δ isoforms display a more restricted tissue distribution. There are high levels 
of p38(MAPK)-γ expression in the skeletal muscles, heart, lungs, thymus and testes (135). 
Similarly, p38(MAPK)-δ is expressed in the lungs and testes but also in the pancreas, small 
intestines, kidneys and epidermis (136). In addition, similar to ERK and JNK, each isoform of 
p38(MAPK) is recognized for its selective affinity for specific upstream activators and 
downstream effectors (137).  
 
1.4.3 SB203580 
SB203580 is a pyridinyl imidazole inhibitor commonly used in an experimental setting to 
elucidate the role of p38(MAPK) in cellular signalling (138). It is well-established that the 
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primary function of SB203580 is to block the catalytic activity of p38(MAPK) by acting as an 
ATP-competitive antagonist (139).  The compound selectively inhibits the α and β isoforms of 
p38(MAPK) with high affinity (140). Most protein kinases are insensitive to SB203580, which 
accounts for its specific action on particular p38(MAPK) isoforms (141). Successful inhibition 
by the drug is dependent on the presence of a threonine residue at position 106 to accommodate 
the 4-flourophenyl moiety of SB203580 (142). Both p38(MAPK)-δ and -γ have large side-chains 
on the residues that occupy this site and although other protein kinases do possess a residue that 
is threonine or smaller at the 106 position, the inhibitory effect of the drug is less potent (143).   
SB203580 is capable of binding to both the activated and inactivated forms of p38(MAPK) with 
equal affinity (144). Several studies have demonstrated that the presence of SB203580 has no 





 by upstream signalling events (143, 145, 146).  
 
1.4.4 p38(MAPK) and MAO-A 
The phosphorylation of p38(MAPK) can be stimulated by reactive oxygen species such 
as hydrogen peroxide (147). Since the reaction catalyzed by MAO-A activity produces hydrogen 
peroxide (43), it is possible that this may, in turn, stimulate p38(MAPK) activity.  Interestingly, 
our research group has shown in several CNS-derived clonal cell lines that activated 
p38(MAPK) inhibits MAO-A by phosphorylation of the Serine 209 residue in MAO-A (148).   
This feedback between MAO-A-generated reactive oxygen species, activation of p38(MAPK), 
and the subsequent de-activation of MAO-A by p38(MAPK) suggests an adaptive, beneficial 
response of p38(MAPK) activation. As a stress-activated protein, p38(MAPK) is well-
recognized as an effector and regulator of many apoptotic pathways (149). Therefore, the 
suggested inverse relationship between these two proteins (and the pro-survival role it might 
play), is not consistent with the understood role of p38(MAPK) as a pro-apoptotic kinase.  
Perhaps this supports the p38(MAPK)-mediated feedback regulation of MAO-A in a manner 
reminiscent of classical antidepressants (148). If a reduction in MAO-A, and possibly the 
subsequent increase in 5-HT, does in fact indicate progression towards cancer as suggested by 
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Rybaczyk et al. (19) then serious consideration must be given to the use of antidepressants 
among cancer patients and those at high risk of developing certain forms of cancer.  
 
1.5 Cancer Progression 
1.5.1 Metastasis 
The survival rate for breast cancer patients has significantly improved in the last 20 years 
(150). This is attributed to a rising public awareness and the development of enhanced diagnostic 
and treatment strategies, among other factors (150). Unfortunately, metastasis, which represents 
a spreading of the tumour from the primary site to other sites within the body, is often associated 
with increasing malignancy and a significantly poorer prognosis (151).  In breast cancer, cells 
most commonly colonize at secondary locations in the lungs, brain, liver and bone (152). 
Metastasis is a series of events that involves the sloughing of cells from the primary tumour and 
their re-localization to a secondary site (153, 154). This multistep process begins with local 
invasion of tumour cells into the healthy surrounding tissue. Subsequently, these cells infiltrate 
neighbouring circulatory vessels in a process known as intravasation (155). Fortunately, less 
than 0.05% of circulating tumour cells will survive travel through the circulation (156). Before 
forming stable metastases, circulating tumour cells must overcome the mechanical stress of 
circulatory transit, adapt to a dynamic environment and escape immune-mediated destruction 
(155). These tumour cells must then exit the blood or lymphatic system (extravasation) (157). At 
this stage undetected tumour cells establish themselves in the new site and may remain dormant 
before proliferating to form a secondary tumour (Figure 5). Efforts to understand the signalling 
events that occur during metastasis have only led to a descriptive understanding of tumour 
progression (158). This task has proven to be difficult, because metastasis is detected at the end 
stages of pathological advancement. The end stage of the disease is marked by genetic 
instability; therefore, the tumour cell population is heterogeneous (159). Under these conditions 
metastatic carcinoma cells, which at this point have minimal presence, are difficult to detect 
(158). To further complicate the issue, during tumour expansion there are  extensive  interactions 




Figure 5. The metastatic process. Cancer cells spread to other parts of the body in a complex 
multistep process known as metastasis. There is first local invasion of cancer cells which 
intravasate into nearby circulatory vessels and are transported to a distant site. The cancer cell 
arrests at the new location and undergoes extravasation before migrating into the surrounding 
tissue and proliferating to form micrometastases (small tumours). Image reproduced with 
permission from reference (160). 
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between tumour cells and surrounding tissues (158). This makes it challenging to isolate and 
observe these cells, and to fully characterize the sequence of molecular events contributing to 
their metastatic behaviour. 
Treatments such as chemotherapy do help to prolong life, and the selection process 
regarding which therapy would best benefit a given patient is increasingly more accurate due to 
the identification of biomarkers (161). The analysis of protein expression at tumour sites has 
proven to be a successful method of better understanding the disease and its advancement. As 
such, a major focus of breast cancer research is the identification of additional markers, 
particularly markers involved in breast cancer progression during the epithelial-mesenchymal 
transition (EMT).  
 
1.5.2 Epithelial-Mesenchymal Transition 
In vitro observations in human breast cancer cell lines clearly demonstrate that a loss of 
epithelial properties preceding the acquisition of mesenchymal features will lead to increasing 
disease aggressiveness (162). It is proposed that EMT, which occurs during embryonic 
development strongly resembles the actions of cancer cells as they undergo metastasis (163). In 
brief, during embryonic development cells that are initially part of the neural tube disengage 
from the parent epithelium and migrate throughout the embryo to specific sites prior to 
differentiation. The mechanism of cell migration and re-establishment in a distant location, 
however, is not entirely lost in adulthood as EMT is also implicated in tissue regeneration, 
wound-healing, organ fibrosis, and perhaps metastasis (164). 
EMT refers to the series of morphological events that involve the cells abandoning the 
primary tumour site to migrate to another location in the body and form a secondary tumour 
(165). Epithelial and mesenchymal cells are the two cell phenotypes that are part of EMT (Figure 
6). Epithelial cells form densely associated tissue layers with minimal intercellular space and 
strong connective junctions along multiple fronts, which is a characteristic of human breast 
cancer tumour cells (166). These cells are described as having apico-basal polarization, meaning 
that membrane proteins are asymmetrically distributed according to placement on either the 
apical (exposed to the extracellular space)  or  basal (attached  to  basal  lamina)  domains  of  the  





Figure 6. The epithelial-mesenchymal transition. Cancerous epithelial cells lose polarity and 
assume a mesenchymal phenotype to gain entry into the vasculature. The highly motile 
mesenchymal-like cancer cells eventually arrest at secondary sites. At this stage cells may 
remain dormant or revert back to the epithelial phenotype.  
Breast Cancer Research. 2011;13(6):228 © 2011 BioMed Central, Ltd. 
Copyright to this article is held by the author(s), licensee BioMed Central Ltd. This is an Open Access 
article: verbatim copying and redistribution of this article are permitted in all media for any purpose, 
provided this notice is preserved along with the article's original citation. 
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plasma membrane (167). The structure of epithelial sheets is maintained by a regulated adhesive 
junction arrangement, which is contingent on the layout of the cytoskeleton and the location of 
cadherin molecules on the plasma membrane. This rigid organization forms a diffusion barrier 
between individual cells (168). During EMT epithelial cells lose cell-to-cell contacts and 
undergo an extensive remodelling of the cytoskeleton. These events are concurrent with the 
expression of mesenchymal elements, which promote a migratory phenotype (169). 
Mesenchymal cells display front-back polarity and are completely surrounded by the 
extracellular matrix (170). The cells develop properties that facilitate motility, such as the 
appearance of long thin processes that extend from a small cell body (167).  
The transition of cells into a mesenchymal form is a reversible process; conversely, the 
expression of adhesion molecules permit dispersed unattached cells to aggregate (171). Reverse 
EMT, commonly referred to as mesenchymal-epithelial transition (MET), is of equal importance 
in normal embryonic development as well as cancer progression (158). For example, following 
extravasation during metastasis, cells experience brief local migration before undergoing MET 
and initiating growth at a secondary tumour site. This system of events is coordinated by a series 
of gene regulatory components including: Slug, Snail, and Twist, of which E-cadherin is a 
downstream target (172). E-cadherin associated with β-catenin, as well as vimentin are generally 




E-cadherin is a transmembrane molecule expressed in all epithelial cells (174). It is a 
classical cadherin protein associated with adheren junctions and maintains strong mechanical 
attachments between cells (175). This transmembrane adhesion protein links the cytoskeleton to 
extracellular structures to accomplish cell-to-cell anchorage (175). This is an indirect connection, 
because the internal linkage is supported by intracellular anchor proteins, such as β-catenin 
(176). Conservation of the epithelial cell shape relies on the proper functioning of this complex 
otherwise disruption may accelerate tumour metastasis (177). The multifunctional cytoplasmic 
protein, β-catenin, regulates cell-cell adhesion by anchoring cadherins to the actin cytoskeleton 
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and may also contribute to the development of invasive carcinoma cells (176). E-cadherin, 
specifically, plays a crucial role in the maintaining epithelial cell interactions and thus has been 
identified as a key suppressor of metastasis (160).   
 
1.5.4 Vimentin 
The expression of vimentin tends to coincide with a reduction in E-cadherin presence 
along the plasma membrane (178). Vimentin is an intermediate filament, thus a major 
cytoskeletal component that forms highly dynamic structures in animal cells and imparts 
mechanical stability in cells of mesenchymal origin (179). Hence, it is a mesenchymal marker 
and its presence is correlated with the EMT (179). Evidently, this suggests a role for vimentin in 
facilitating cell migration, which is further supported by the expression of vimentin-like 
intermediate filament proteins at sites of elongation (180). In mammals vimentin is the most 
prevalent intermediate filament protein (180). Kokkinos and colleagues (181) compared three 
human breast cancer cell lines: (1) MCF-7 (poorly invasive, non-metastatic); (2) MDA-MB-231 
(moderately invasive and metastatic); and (3) MDA-MB-435 (highly invasive and metastatic). 
Immunostaining revealed that the more aggressive the cell line, the greater the expression of 
vimentin.  
Histological analyses have identified vimentin in over 90% of grade three (most aggressive) 
breast carcinomas (182). Vimentin expression in mammary glandular tissues has not been as 
consistent, and this is attributed to the variable expression of the protein in micrometastases 
versus macrometastases (181). There is a possibility that the mesenchymal properties featured in 
undetectable newly formed tumours are lost as the mass of cells becomes progressively larger 
and an epithelial phenotype becomes increasingly beneficial for tumour establishment 
(occurrence of the MET) (183).  Although studies have proposed that vimentin is not only an 
indication of EMT, but also of invasive breast cancers, experts remain uncertain about its 
prognostic values (184, 185). Vimentin may be one marker for EMT; however, more specific 
markers are necessary to influence outcome predictions. 
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1.5.5 Tumour heterogeneity  
To further complicate matters, breast cancer researchers have become well aware of the 
heterogeneous collection of cancer cells within a single breast tumour (159, 186-188). 
Immunohistochemical evaluations have undisputedly revealed that mammary tumours frequently 
consist of cells with varying levels of tumour marker expression, thus distinct morphology and 
behaviour (186). In a study conducted by Wild and colleagues (187), it was demonstrated that 
97% of the epithelial breast carcinomas observed, displayed tumour heterogeneity. Moreover, 
tumour cells exhibited genetic evolution according to host pressures and treatment interventions 
(189). Intra-tumour heterogeneity provides a possible explanation for acquired drug resistance 
particularly in advanced stages of cancer. Over time, the genetic instability of tumour cells gives 
rise to new characteristics contributing to subsequent growth advantages (159). Shen and 
colleagues (188) reported that double-stranded breaks influenced chromosomal instability giving 
rise to new cellular characteristics in later stages of cancer. Consistent with these findings, 
Goldie and Coldman (190) established that the size of the tumour was positively correlated with 
the rate of development of tumour resistance, because of the greater potential for the occurrence 
of drug resistant cancer cells in a larger tumour population. 
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1.6 Rationale, Hypothesis & Objectives 
Overall, there are three main studies which inspired us to examine the novel interaction 
of MAO-A and p38(MAPK) in breast cancer. The first was a recent report by Rybaczyk and 
colleagues that indicated significant losses of MAO-A status [e.g. mRNA] in 95% (!) of human 
cancers. The second was a group of studies implicating the activation of p38(MAPK) in breast 
cancer progression. The last study came from our research group in which we reported the 
regulation of MAO-A by p38(MAPK) in glial cells. Given these findings we questioned whether 
the activation of p38(MAPK) inhibits MAO-A function in breast cancer cells leading to the 
progression of the disease (Figure 7). The hypothesis states that a functional interaction between 
the p38(MAPK) and MAO-A systems alters breast cancer cells in an ER-dependent manner.  
The objectives of this thesis are supported by the literature and include: 
(i) To determine the extent that the chemical or molecular inhibition of MAO-A and/or 
p38(MAPK) affects breast cancer cell tumourigenic or metastatic potential in vitro. 
(ii) If MAO-A and/or p38(MAPK) inhibition affects cell phenotype, then to determine 
whether p38(MAPK) regulates MAO-A-sensitive phenotypes in an ER-dependent 
manner. 
  




























             
   
Figure 7. Proposed interaction between p38(MAPK) and MAO-A. Based on previous work 
in the literature we suggest that MAO-A is inhibited by both CLG and p38(MAPK) (148). The 
inhibition of activated p38(MAPK) by SB203580 should induce opposite effects of CLG. We 
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2 MATERIALS AND METHODS 
All reagents and materials were obtained from commercial sources (Table 1) unless otherwise 
indicated. The antibodies used are presented in Table 2. 
 
Table 1. Reagents and commercial suppliers. 
 
Reagents & Materials Company Address 
Acrylamide Bio-Rad Laboratories Hercules, CA, USA 
Agarose  Invitrogen Carlsbad, CA, USA 
APS Sigma-Aldrich St. Louis, MO, USA 
Aqueous Counting Scintillant Amersham Biosciences Piscataway, NJ, USA 
BCA Protein Assay Kit Pierce Rockford, IL, USA 
Bovine Insulin Sigma-Aldrich St. Louis, MO, USA 
Bovine Serum Albumin Sigma-Aldrich St. Louis, MO, USA 
Bromophenol Blue Sigma-Aldrich St. Louis, MO, USA 
Cell Freezing Media Invitrogen Carlsbad, CA, USA 
Clorgyline Research Biochemical Int’l Natick, MA, USA 
[
14
C]-radiolabeled serotonin PerkinElmer Waltham, MA, USA 
DAPI Nucleic Acid Stain Invitrogen Carlsbad, CA, USA 
DMSO EM Science Gibbstown, NJ, USA 
DTT Cell Signaling Technology Danvers, MA, USA 
Enhanced Chemiluminescence GE Healthcare Uppsala, Sweden 
FBS Invitrogen Carlsbad, CA, USA 
Film (X-OMAT LS) KODAK Rochester, NY, USA 
Formalin EMD Chemicals Gibbstown, NJ, USA 
Glycerol J.T. Baker Phillipsburg, NJ, USA 
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Glycine Sigma-Aldrich St. Louis, MO, USA 
Haemotoxylin Invitrogen Carlsbad, CA, USA 
HEPES Invitrogen Carlsbad, CA, USA 
L-glutamine Invitrogen Carlsbad, CA, USA 
Matrigel Basement Membrane Matrix BD Biosciences Mississauga, ON, Canada 
α-MEM Sigma-Aldrich St. Louis, MO, USA 
MEM Vitamin Solution Invitrogen Carlsbad, CA, USA 
2-Mercaptoethanol Sigma-Aldrich St. Louis, MO, USA 
Methanol Fisher Scientific Fair Lawn, NJ, USA 
Dako Mounting Media Dako Carpinteria, CA,USA 
MTT Sigma-Aldrich St. Louis, MO, USA 
NaCl Fisher Scientific Toronto, ON, Canada 
Nitrocellulose Membrane Bio-Rad Laboratories Hercules, CA, USA 
PageRuler Protein Ladder Thermoscientific Logan, UT, USA 
Pen-Strep Invitrogen Carlsbad, CA, USA 
PIC Sigma-Aldrich St. Louis, MO, USA 
RPMI-1640 Sigma-Aldrich St. Louis, MO, USA 
SB203580 Invitrogen Carlsbad, CA, USA 
SDS J.T. Baker Phillipsburg, NJ, USA 
Tween
®
 20 EM Science Gibbstown, NJ, USA 
TEMED  Bio-Rad Laboratories Hercules, CA, USA 
Tris-Base Fisher Scientific Toronto, ON, Canada 
Tris-HCl ICN Biomedicals Aurora, OH, USA 
Triton X-100 Sigma-Aldrich St. Louis, MO, USA 
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Trypsin-EDTA Sigma-Aldrich St. Louis, MO, USA 
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Table 2. Antibodies and commercial suppliers. 
 
Primary Antibody Dilution Company Address 
MAO-A (H-70) 1:250 Santa Cruz Biotechnology Santa Cruz, CA, USA 
E-cadherin (24E10) 1:1000 Cell Signaling Technology Danvers, MA, USA 
Monoclonal Anti-
Vimentin 
1:1000 Sigma-Aldrich St. Louis, MO, USA 
p-p38(MAPK) 
(T180/Y182) (28B10) 
1:200 Cell Signaling Technology Danvers, MA, USA 




p-GSK3β (Ser9): Sc 
11757R 
 








Santa Cruz Biotechnology 
 
Cell Signaling Technology 
St. Louis, MO, USA 
 
Santa Cruz, CA, USA 
 
Danvers, MA, USA 
Secondary Antibody Dilution Company Address 
Goat-Anti-Mouse IgG 1:2000 Bio-Rad Laboratories Hercules, CA, USA 
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8% SDS; 40% glycerol; 10% β-
mercaptoethanol; 0.02% bromophenol blue; 





1g NaHCO3; 5g MgSO4; 500 mL H2O
Lysis Buffer 1% Triton-X 100; 20 mM Tris, pH 7.5; 10% 
glycerol; 1 mM EDTA; containing 100X 
protease inhibitor cocktail
PLC Lysis Buffer 50mM HEPES pH 7.5, 50 mM NaCl; 10% 
Glycerol; 1% Triton X-100; 1.5 mM MgCl2; 
1 mM EGTA; 10 mM Na-PPi; 100 mM NaF 
10X Running Buffer 30.3 g Tris; 144 g glycine; 10 g SDS; 1 L 
H2O 
Buffer A   18.5 g Tris-HCl; 77 g Tris; 2 g SDS pH 8.8  
(per 500 mL) 
 
Buffer C      30.0 g Tris-base; 2 g SDS pH 6.8 
       (per 500 mL)       
 
1X Transfer Buffer 3 g Tris-base; 14.4 g glycine; 37.5 mg SDS; 
200 mL methanol; 800 mL H2O 
 
TBS 3 g Tris-base; 8 g NaCl; taken to 1000 mL 
with H2O 
  
TBST       500 µL Tween
®
 20; 1 L of 1X TBS 
  
K+ Buffer     181.6 mL 1M K2HPO4; 18.4 mL 1M 
    KH2PO4; taken to 1 L with H2O; pH 7.85 
 









Table 4. Characterization of MCF-7 and MDA-MB-231 breast cancer cell lines. 
Cell line ER PR HER-2 E-cadherin Vimentin Invasiveness 
MCF-7 positive positive negative positive negative non-invasive 









Figure 8. In vitro assays used to analyze cancerous cell behaviour and phenotype. The 
assays displayed on the right are those experiments that are used to study the adjacent metastatic 
event represented on the left. In this study, the EMT and MET have been examined using 
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2.2 Subculture Protocol 
The estrogen receptor-positive human breast carcinoma MCF-7 cell line and estrogen receptor-
negative human breast carcinoma MDA-MB-231 cell line were obtained from the American 
Type Culture Collection (ATCC). The cells were maintained according to ATCC standards at 
37°C and 5% CO2 in a humidified atmosphere. MCF-7 cells were cultured in Alpha Minimum 
Essential Medium (α-MEM) supplemented with 10% Fetal Bovine Serum (FBS), 1% L-
glutamine, 1% Pen-strep and 10 µg/µL bovine insulin. The MB-231 cells were cultured in 
RPMI-1640 medium supplemented with 10% FBS and 1% Pen-Strep. We chose to use these two 
cell lines so as to align with other studies and reports that often compare and contrast the two. 
The same method of cell passage was used for each cell line. The volumes described in this 
protocol are for cells kept in 100 mm cell culture dishes.  
1. Warm media and 0.25% (w/v) Trypsin-0.53 mM EDTA (T/E) solution in a 37°C water 
bath. 
2. Aspirate off the culture media from the culture dish. 
3. Add 3 mL of the T/E solution to the flask and incubate at 37°C for 5 min or until cells 
detach. 
4. Add 3 mL of complete growth medium and gently wash cells off plate. 
5. Transfer the cell suspension to a 15 mL centrifuge tube. Centrifuge at 1000 g for 5 min at 
RT. Discard the supernatant. 
6. Resuspend the cell pellet in 1 mL of fresh growth medium. Add appropriate aliquots of 
the cell suspension to sterile 100 mm culture dishes containing 10 mL of fresh growth 
media. 
7. Tilt dish side-to-side to ensure even distribution of cells on growth surface and then place 
in the humidified incubator. 
8. If necessary, cells can be stored in Cell Freezing Media and placed in liquid nitrogen for 
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2.3 MAO-A Activity Assay 
The MAO-A activity within a given sample can be measured by introducing [
14
C]-radiolabeled 
serotonin [5-hydroxytryptamine (5-HT)] and analyzing the rate of 5-hydroxytryptamine 
conversion to its acid metabolite [
14
C]-5-hydroxyindole acetaldehyde.  
1. Bubble oxygen through the potassium phosphate buffer for at least 20 min at RT. 
2. Collect and harvest cells. Resuspend the pellet in 100-200 µL of K+ buffer, depending on 
the size of the pellet, and use multiple up-and-down passages through a 22Gi syringe to 
disrupt the cell membrane.  
3. Perform the BCA protein assay to determine the protein concentration of each sample 
and dilute to equal concentrations of 1-2 µg/µL in K
+
 buffer. 
4. In a scintillation vial prepare the working solution (WS: 1X total 5HT substrate) in the 
designated radioactive work area. Note that each sample tested should include one blank 
and three replicates.  
  Sample calculation for WS:  
 
  9 samples x (1 blank + 3 reps) = 36 samples 
  36 samples x 50 µL WS/ sample = 1 800 µL WS required 
  1 800 µL / 100 = 18 µL 
  18 µL / 2 = 9 µL 
  
Therefore, you will require 9 µL of 5-HT standard and 9 µL of [
14
C]-radioisotope (1:1 
ratio). Bring to volume with 1 782 µL of K
+
 buffer.  
 
5. Add 25 µL of 3M HCl to each ‘blank’ (this will inactivate any enzyme function and will 
provide a ‘background’ for the radioenzymatic assay). Place all samples in a 37°C water 
bath at the same time, for 10 min. 
6. Add 25 µL of 3M HCl to all sample tubes except the blanks.  
7. Remove samples from water bath and add 1 mL of a 1:1 H2O saturated ethyl acetate: 
toluene solution. 
8. Briefly vortex each sample and centrifuge (high speed) for 30 sec at RT. 
9. Remove 700 µL of the upper layer and place into separate scintillation vials. 
10. Add 4 mL of ACS cocktail to each scintillation vial and vortex. 
11. Measure C14 activity using scintillation spectrometer.  
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2.4 MTT Assay 
This technique can be applied to measure cell viability by assessing the amount of metabolically 
active cells within a sample. It is a recognized method for monitoring the effect of drugs on cell 
viability or function. A yellow tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; MTT), is enzymatically reduced to insoluble purple formazan 
crystals. By using a detergent to solubilize the crystals, the resulting coloured solution can be 
analyzed by spectrophotometry. The resulting optical density values are relative to the 
conversion of MTT and ultimately to cell function.  
1. Seed 1.0 x 104 cells in 200 µL of media into each well of a 96-well plate. Incubate at 
37°C and 5% CO2 for 2 hours to allow cells to adhere to surface. 
2. Replace media with treatment media (CLG: 1 µM; SB203580: 10 µM) and incubate 
overnight at 37°C and 5% CO2. 
3. Prepare MTT solution at a final concentration of 5 mg/mL dissolved in DMEM 
supplemented with 1% FBS. 
4. Replace media in wells with 50 µL of the MTT solution. Blank (background) wells will 
hold 150 µL of dimethyl sulfoxide (DMSO). 
5. Gently agitate plate to mix and then incubate at 37°C for 2 hours for metabolism to occur.  
6. Add 150 µL of DMSO to all wells except blanks which will receive 50 µL of the MTT 
solution. Gently agitate plate and incubate at 37°C for 30-45 min. 
7. Read optical density at 570 nm. 
 
2.5 Growth Curves Protocol 
The rate at which a tumour is able to grow is an indicator of the aggressiveness of the cancer 
cells. In order to analyze the cell’s growth rate, a series of growth curves were produced as 
follows: 
1. Seed equal numbers of cells to 100 mm culture dishes and treat accordingly (Vehicle; 
CLG, 1 µM; SB203580, 10 µM; CLG + SB203580). 
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2. Treat cells on Day 1 and replace with new growth media (including appropriate drug 
concentrations) every 48 hours.  
3. Cells were harvested and counted using a hemocytometer. The concentration of cells in a 
1 mL cell suspension was determined. The hemocytometer consists of nine 1 mm squares. 
The average of four 1 mm squares was determined and multiplied by 1.0 x 10
4
 to calculate 
the number of cells per mL. This was done every 24 hours for a total of 4-7 days. 
 
2.6 BrdU Assay 
During the DNA synthesizing phase, or S-phase, of cell division, the synthetic thymidine analog, 
5-bromo-2-deoxyuridine (BrdU), will be substituted into a cell’s DNA in place of the 
endogenous thymidine nucleotide. The incorporation of this reagent allows for the detection of 
newly synthesized DNA based on immunodetection of the incorporated BrdU using a specific 
antibody. 
1. Cells are plated on an 8-well chamber slide at 5.0 x 103 cells per well and incubated at 
37°C at 5% CO2 overnight. 
2. Prepare the BrdU solution to a final concentration of 10 µM in culture media. 
3. Aspirate media from chambers being careful not to disrupt the cell layer. Replace with 
300 µL of the BrdU solution and incubate at 37°C at 5% CO2 2 hours. 
4. Remove the BrdU-labelling reagent and wash very gently with PBS without rocking. 
5. Fix cells with 10% formalin, rocking slowly at RT for 20 min. 
6. Wash with PBS in 1% Triton X-100 at RT for 15 min. 
7. Add 200 µL of 2N HCl to denature the DNA and incubate at 37°C for 1 hour. 
8. Aspirate the 2N HCl from each well and neutralize the cells with borate buffer, pH 8.5, by 
washing 3X at RT for 10 min intervals. 
9. Wash cells with PBS and incubate in blocking solution (PBS in 0.3% Triton X-100, 5% 
goat serum) rocking at RT for 30 min. 
10. Prepare the fluorescent conjugated anti-BrdU antibody at a 1:500 dilution in blocking 
solution. Incubate the cells at 4°C overnight. 
11. Wash cells 3X in PBS at RT for 10 min intervals. 
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12. Incubate cells at RT for 2 hours in secondary goat anti-mouse (visualized as a red colour 
upon fluorescing) at a 1:250 dilution in blocking solution. 
13. Wash 3X in PBS at RT for 10 min intervals. 
14. Counterstain with DAPI nucleic acid stain (visualized as ‘blue’) at RT for 5 min. Wash 
3X in PBS at RT for 10 min intervals. 
15. Mount dry samples with Dako mounting medium and analyze slide with a fluorescence 
microscope. 
 
2.7 Foci Formation Protocol 
Foci formation assays assess contact-inhibited growth of breast tumour cells. Once 100% 
confluence is reached and a monolayer of cells is formed, transformed cells will grow on top of 
one another to eventually form foci. 
1. Seed 1.0 x 105 cells per 100 mm plate and maintain in recommended growth media for 10-
14 days depending on the cell line. Ensure an even distribution of cells on the plate 
surface after seeding. 
2. Change the media every 72 hours and more frequently with increasing confluence. Once 
100% confluence is reached, the cells are grown for an additional 5 days to allow for foci 
formation upon the monolayer. 
3. Place the plates on ice and wash carefully with ice-cold 1X PBS by adding it slowly down 
the side of the plate to avoid lifting of the cell monolayer.  
4. Fix the cells in 4 mL of ice-cold methanol and store overnight at 4°C. 
5. Remove the methanol and leave plates to air dry on ice. 
6. Add 4 mL of a filtered 1:10 dilution of crystal violet to each plate and incubate at RT 
rocking gently overnight.  
7. Rinse the plates using ddH2O until such time as all the stain is removed and then leave the 
plates to dry at RT.  
8. Examine the plates under a BX71 Olympus microscope for the presence of foci (cells that 
have grown over each other to form a cluster or focus). Dark purple spots represent such a 
focus.  
 Page | 39  
 
2.8 Soft Agar Assay  
This assay was conducted to determine the potential for contact inhibition and anchorage-
independent growth in the breast cancer cell lines. Normal cells require contact (i.e. need to be 
‘anchored’) with a solid surface to allow for cell division. When cells are suspended between two 
gel surfaces the lack of contact with a solid surface will impede growth of a normal cell, but not 
the growth of a transformed cell. Normal cells will also grow to a monolayer and then once they 
come in contact with surrounding cells, will stop dividing. Thus, in vitro models of cellular 
transformation involve the acquisition of cancerous properties such as the ability of cells to grow 
over each other (due to a loss of contact inhibition) and to form colonies in semi-solid agar 
(anchorage-independence growth).  
1. In a 60 mm petri dish, add the bottom agar layer (0.61%) (Table 5) which provides a 
nutrient base. To ensure that the agar is completely and evenly solidified, incubate plates 
at RT for 30 min. Particular attention should be used to avoid disturbing the high-
percentage agar layers in these plates. 
2. Collect cells and suspend 5.0 x 104cells per plate in the (0.36%) (Table 5) semisolid agar 
top layer mixture, including appropriate drug treatments (CLG: 1 µM; SB203580: 10 
µM). Include at least three replicates per treatment group. 
3. To provide additional nutritional supplements and prevent drying of the cells, 2 mL of top 
agar solution supplemented with indicated drug concentrations (excluding the agar) are 
added to each plate every 7 days. 
4. Incubate plates for 30 days at 37°C in a 5% CO2 incubator. At the end of 30 days, the cells 
are counted using a BX71 Olympus microscope at 10X magnification. The average colony 
count is based on three randomly chosen fields per experiment. 
Determine the number of plates that are required and prepare the appropriate amount of bottom 
and top agar mixtures as instructed below, based on having 5 mL per plate. The volumes 
indicated are for 4 (60 mm) cell culture dishes. 
  










Table 5. Soft agar assay. Top and bottom agar volumes and materials.  
 Bottom Agar (0.61%) Top Agar (0.36%) 
Growth Media (with drug) 10.2 mL 4 mL 
100 X MEM 1 mL 0.3 mL 
dH2O - 1.3 mL 
FBS 2 mL 0.8 mL 
1.8 % Agar 6.8 mL 1.6 mL 
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2.9 Migration and Invasion Assay 
Migration and invasion assays follow essentially the same protocol, the only exception is that in 
a migration assay cells are migrated across a porous membrane (Figure 9A), whereas invasion 
requires the migration through a matrix barrier, typically matrigel or an endothelial monolayer. 
EA.hy926 cells are a human endothelial cell line used to observe transendothelial migration. The 
use of matrigel models the movement of cancer cells through the basement membrane, which a 
cancer cell must do once it detaches from the primary tumour and invades the surrounding tissue 
on its way to the circulatory system to begin the pathway to metastasis. Similarly, an endothelial 
cell layer between the breast cancer cells and the supporting filter membrane is used as a model 
of the barrier that these cells must breach when moving into (intravasation) and out of 
(extravasation) circulatory vessels (Figure 9B).  
The human endothelial cell line, EA.hy926, was provided by Dr. Paul Mellor (Cancer Research 
Unit, Saskatoon). The cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% FBS.  
a)  Invasion: seed the EA.hy 926 cells at 5.0 x 10
5
 cells per Transwell filter 72 hours 
before the migration assay to allow the formation of a complete endothelial 
monolayer. 
b)  Matrigel: prior to migration, coat the filters with 50 µL of 1 mg/mL matrigel and 
incubate at 37°C for 4 hours.  
1. The breast cancer cells were serum starved for 24 hours before performing the migration 
assay by replacing cell media with 0.5% FBS containing media. 
2. Before seeding cells into the upper chamber carefully aspirate off EA.hy926 cell media/ 
remaining matrigel liquid being cautious not to puncture the monolayer/matrigel.   
3. Collect serum-starved breast cancer cells (incubated in 0.5% FBS, 24 h) and resuspend in 
0.5% FBS media at a concentration of 4.0 x 10
5
cells/mL. Aliquots (500 µL) of this cell 
suspension are then layered onto each filter. 
 
  



















Figure 9. In vitro and in vivo migration and invasion. (A) In a Transwell system, the cancer 
cells migrate through the filter membrane along the concentration gradient toward the 
chemokine. (B) During carcinogenesis, epithelial cells alter their adhesion properties to facilitate 
expansion into adjacent tissues. These cells must degrade the basement membrane and undergo 
transendothelial migration prior to renewed proliferation at a secondary site.  
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4. Incubate cells for 2 hours allowing cells to adhere to the surface and then administer 
appropriate drug treatments. Incubate the treated cells for a 24 hour (EA.hy926) or 72 
hour (matrigel) period. 
5. To assess cell migration, the media is removed from the upper chamber. Cells that did not 
migrate are carefully removed from the upper side of the filter membrane using a cotton 
swab.  The inserts are then immersed in ice cold methanol and stored at -20°C overnight.   
6. Remove the methanol from the upper chamber and rinse in Scott’s water. The cells are 
stained with haemotoxylin for 30 min at RT.  
7. After emptying the insert, it is again washed in Scott’s water for 5 min at RT. 
8. The inserts are then dehydrated through increasing ethanol concentrations of 50%, 75%, 
90% and 95% for 1 minute intervals. The filters are left to air dry completely before 
removing the filter membranes and mounting them onto a microscope slide with Dako 
Flourescent Mounting Media.  
9. Using a BX71 Olympus microscope count migrated cells across 5 fields at 20X 
magnification. 
 
2.10 Immunoblotting Protocol 
Immunoblotting (also known as Western blotting) is based on the separation of proteins by gel 
electrophoresis as a function of their molecular weight (MW) and then transferring the separated 
(resolved) proteins to a membrane. Proteins are identified using a primary antibody specific for 
that protein which is then detected by a secondary antibody that not only recognizes the first 
antibody, but that is also conjugated to an enzyme. The enzyme, most often horse radish 
peroxidase (HRP), converts a substrate to a light-emitting product that can then be detected using 
film. The identification and/or detection of the protein(s) is then compared to a protein ladder 
which has been run on the same gel and that contains proteins of known molecular weight. 
A. Sample Preparation 
1. Harvest and lyse cells using appropriate amounts of lysis buffer. 
2. Incubate on ice for 30 min. 
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3. Centrifuge samples for 10 min at 12 000 g at 4°C. Use this pre-cleared sample (the 
supernatant) to perform the bicinchoninic acid (BCA) assay to determine the total protein 
concentration for each cell lysate. 
4. Prepare aliquots of 1-2 µg/µL by diluting the sample with PLC lysis buffer and 4X 
loading buffer. 
5. Boil the samples for 5 min at 95°C (to denature the proteins so that they migrate freely 
during the gel electrophoresis) and store at -20°C until needed. 
B. Gel electrophoresis 
1. Standard immunoblotting protocols are based on protein separation according to 
molecular weight using SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis). The polyacrylamide gel is prepared as follows in Table 6. 
2. Bathe the gel apparatus in 1X running buffer diluted from a 10X stock solution added into 
the gel holder. 
3. To determine protein size and to monitor protein migration along the gel, a molecular 
weight marker (PageRuler Protein) was loaded onto the gel. Equal amounts of protein are 
loaded into each well (usually between 20-40 µg). 
4. Apply a constant voltage of 110 V to the resolving gel apparatus and allow proteins to 
resolve for approximately 90 minutes. 
C. Transfer 
The proteins are transferred from the gel onto a nitrocellulose membrane. 
1. Place the nitrocellulose membrane next to the gel and together they are sandwiched 
between absorbent paper and sponges (see Figure 10). 
2. Remove air bubbles and submerge the sandwich in 1X transfer buffer. The transfer buffer 
is constantly stirred and kept ice cold so as to keep the temperature of the solution from 
heating (as would be expected from running the system  at 0.23 A for 90 min). 
D. Immunodetection 
Once the proteins have been transferred to the nitrocellulose membrane, remove the membrane 
and incubate it in a blocking solution (5% milk casein in 1X TBS; 1 h, RT) to block all non-
specific binding sites on the membrane. 
  











Table 6. Preparation of SDS polyacrylamide gel. Volumes listed are for a 1 mm gel thickness. 
 
 10% Resolving Gel 4% Stacking Gel 
ddH2O 4.01 mL 3.00 mL 
Buffer A 2.50 mL - 
Buffer C - 1.25 mL 
Acrylamide* 3.33 mL 0.67 mL 
10% APS 50 µL 25 µL 
10% SDS 100 µL 50 µL 
TEMED 10 µL 5 µL 
 


































Figure 10. Assembly of the blotting sandwich during protein transfer. Proteins are 
transferred in an electrical field from the gel onto the membrane. The negatively charged 
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1. Dilute the primary antibody in 1X TBST at the concentration suggested by the individual 
commercial sources. The membrane/antibody solution is sealed in a fitted plastic bag and 
placed between two glass plates (the pressure from the plates keeps the bag flat and the 
solution evenly distributed over the membrane). This is incubated overnight at 4°C. 
2. Wash the membrane 3X in 1X TBST at RT rocking for 10-15 min.    
3. Add the HRP-conjugated secondary antibody to 20 mL of 5% milk in TBST at the 
suggested dilution and rock the membrane in this solution at RT for 1-2 hours.   
4. Wash the membrane 3X in TBST at RT for 15-20 min. 
E. Detection 
1. Prepare ECL (enhanced chemiluminscence) detection reagent and allow it to warm to RT. 
2. Incubate the membrane in the ECL reagent for 1 min, then remove it and allow excess 
ECL solution to drain off. Place the membrane in a film cassette and cover with a thin 
piece of transparent plastic (keeps the film from getting wet) and then expose to x-ray 
film. 
3. Expose the film and if needed re-expose the membrane to more film for varying amounts 
of time to optimize the detection of the protein band.    
Each immunoblotting experiment also includes the detection of a housekeeping protein, e.g. β-
actin, as an ‘internal control’ to demonstrate that equal amounts of cellular protein was loaded 
into each lane on the gel. 
 
2.11 Immunocytochemistry 
Immunofluorescence techniques were used to examine the expression and distribution of 
markers of the epithelial-mesenchymal transition (EMT) in treated cell cultures: These markers 
include E-cadherin, vimentin, and β-catenin. 
1. Seed 5.0 x 103 cells per well of an 8-well chamber slide and incubate at 37°C in 5% CO2 
for 2-4 hours to allow cells to adhere to the slide surface. 
2. Without disrupting the cells, gently wash cultures in 1X PBS. 
3. Fix cells with 10% formalin, rocking slowly at RT for 20 min. 
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4. Gently wash cells twice in 1X PBS before adding blocking solution (1.5 mL donkey 
serum, 900 µL 10% Triton X-100, 27.6 mL 1X PBS). Block cells rocking at RT for 30 
min. 
5. Prepare the primary antibody in blocking solution. Incubate cells in primary antibody 
rocking at 4°C overnight. 
6. Wash the cells 3X in 1X PBS at 10 min each. 
7. Prepare the fluorescent secondary antibody at a 1:200 dilution. Incubate cultures for 2 
hours rocking at RT.  
8. Wash the cells 3X in 1X PBS at 10 min each. 
9. Counterstain with DAPI at RT for 5 min. Wash 3X in PBS at RT for 10 min each. 
10. Mount dry samples with Dako mounting medium and analyze slide for the distribution 
and intensity of the target proteins. 
11. The distribution of E-cadherin and vimentin within cells was analyzed by collecting the 
fluorescence intensity along a bisecting line centered on the nucleus and the relative 
quantity of proteins (based on intensity)  in the nucleus/cytoplasm was quantitated using 
ImageJ 1.32j (http://rsb.info.nih.gov/ij/).  
2.11.1 Statistical Analysis 
Data are expressed as mean ± SEM. Significance (set at P<0.05) was assessed either by Student's 
t-test (for comparing two means) or by analysis of variance (ANOVA: for comparison of 3 or 
more means) with post-hoc analysis relying on Bonferroni's Multiple Comparison Test 
(GraphPad Software, Inc., San Diego, CA). 
2.12 Nuclear Fraction Protocol 
This subcellular fractionation procedure allows for the separation of membrane, cytoplasmic and 
nuclear cell fractions (Figure 11). This protocol should be carried out at 4°C at all times. 
1. Cells were grown on 100 mm plates. 
2. Cells are transferred to an eppendorf tube using T/E and original growth media to 
neutralize and transfer. This portion of the protocol is non-sterile and can be performed at 
RT. 


























Figure 11. Nuclear protein fractionation. The application of centrifugation methods (indicated 








Nuclear Extract Nuclear Matrix 
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3. Make up the hypotonic and extraction buffers according to the total volume required, 
depending on the pellet size (Table 7). 
4. Depending on the size of the pellet add the appropriate volume of hypotonic buffer to 
each tube and disrupt cells using a pestle with the same number of strokes in each tube 
(10-20). 
5. Centrifuge sample at 3000 rpm for 5 min at 4°C. Then collect the supernatant in a new 
eppendorf tube, this is the cytoplasmic fraction (cytosolic proteins). 
6. Resuspend pellet in the extraction buffer mixing before adding to each tube. Rock for 20 
min at 4°C before centrifuging samples at 15 000 rpm for 10 min at 4°C. 
7. The supernatant contains the nuclear extract (nucleic acid binding proteins) and the pellet 
contains the nuclear matrix (insoluble nuclear proteins). 
 
2.13 Transfection protocol 
The introduction of foreign DNA into mammalian cells allows for the expression of the protein 
encoded by that DNA. We introduced DNA that encodes for the green fluorescent protein (GFP) 
and MAO-A variants to visualize cells using fluorescence microscopy. This was accomplished 
using the following transfection protocol: 
1. Prior to transfection cells were seeded in a 100 mm culture dish in 10 mL of growth 
medium (plate should be over 75-80% confluent at the time of transfection). 
2. At the time of transfection: 
a. Dilute 24 µg of plasmid DNA in 1.5 mL of Opti-MEM I Reduced Serum Medium 
without serum and gently mix. 
b. Gently mix LipofectamineTM 2000 before diluting 60 µL in 1.5 mL of Opti-MEM 
I Medium. Gently mix and incubate at RT for 5 minutes. 
 
3. Combine the diluted plasmid DNA with the diluted LipofectamineTM 2000 solution, mix 
gently and incubate at RT for 20 min to allow DNA- Lipofectamine
TM
 2000 complexes to 
form. 







Table 7. Nuclear protein fractionation. Concentrations of reagents for the hypotonic and 
extraction buffers. 
Reagents Final Concentration 
1 M HEPES pH7.0 20 mM 
1 M KCl 10 mM 
1 M DTT 0.5 µM 
10% Triton X-100 0.1% 
100% Glycerol 20% 
500 mM PMSF 2 mM 
1 mg/mL Aprotinin 5 µg/mL 
1 mg/mL Leupeptin 5 µg/mL 
5 N NaCl 420 mM* 
H2O -to final volume- 
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4. 3 mL of the solution is added to each culture plate containing the adhered cells and 
medium. To ensure that the solution is evenly distributed gently rock the plates back and 
forth. 
5. Following 4-6 hours of incubation at 37°C replace media with new growth media. 
6. Incubate cells for 24 hours at 37°C in a 5% CO2 incubator. 
7. To use the transfected cells for separate assays, harvest the cells from each culture dish. 
The pellet can then be used immediately in experimental procedures.   
 
2.14 DSS and BS
3 
Cross-linker Protocol 
A crosslinking experiment was conducted to investigate the subcellular localization of MAO-
A in MB-231 versus MCF-7 cells. Proteins, such as MAO-A, have several primary amines as 
part of the side chain of lysine (K) residues and in the N-terminus of each polypeptide. These 
primary amino groups (-NH2) are targeted by such N-hydroxysuccinimide (NHS) esters as 
disuccinimidyl suberate (DSS) and its analog bis[sulfosuccinimydyl] suberate (BS
3
) (191). NHS 
esters form stable amide bonds with primary amino groups in pH 7-9 buffers, resulting in the 
release of N-hydroxysuccinimide. DSS is hydrophobic and membrane-permeable allowing for 
intracellular conjugations, whereas BS
3
 is hydrophilic and useful for cell-surface protein 
crosslinking (191). Both water-soluble and insoluble forms have essentially identical reactivity 
with primary amines.  
1. Cells were treated for 24 hours with CLG and/or SB203580 at 1 µM and 10 µM, 
respectively prior to harvest. Crosslinking is performed on cells in suspension, following 
the collection of a cell pellet (2.5 x 10
7
 cells/mL) in an eppendorf tube (Subculture 
Protocol).  
2. The pellet is washed 3X in ice-cold PBS to remove amine-containing culture media. 
3. Crosslinkers are prepared by: 
a) dissolving BS
3
 in H2O in the required volume at a 25 mM concentration. 
b) dissolving DSS in DMSO in the required volume at a 25 mM concentration. 
4. The pellet is resuspended in the DSS or BS3 solution made in PBS to a final 
concentration of 1 mM. 
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5. The reaction mixture is incubated at RT for 30 min.  
6. Add glycine to a final concentration of 10 mM to quench the reaction and incubate at RT 
for 15 min. 
Pellet undergoes a final wash in PBS preceding protein determination and western blot analysis. 
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3 RESULTS 
Please note that the ‘Results’ section includes a discussion of the results at each step for 
ease of interpretation and to provide rationale for the choice of subsequent experiments. A 
general discussion is presented following this section. 
The MCF-7 and MB-231 breast cancer cell lines are both derived from malignant human 
adenocarcinomas isolated from pleural effusions (192, 193) and are the most widely used breast 
cancer cell lines in research (194). These cell lines are largely studied to examine hormone 
dependence in breast cancer. The MCF-7 cells are classified as ER(+) [ER(+), PR(+), HER-2(-)] 
(195), whereas the MB-231 cells are classified as a triple negative breast cancer [ER(-), PR(-), 
HER-2(-)] (196). We chose these cell lines so as to align with other reports that often compare 
and contrast the two.  
An initial investigation corroborated that the MB-231 cells represent a more aggressive 
cancer cell line as observed in other studies (197). For instance, an indication of aggressiveness 
is the spindle-shaped morphology of MB-231 cells, which can be associated with a 
mesenchymal-like phenotype supportive of invasive behaviour (171). 
MAO-A and p38(MAPK) protein expression was compared between the MCF-7 and 
MB-231 cell lines using immunoblotting. The MB-231 cells clearly express higher MAO-A 
expression than the MCF-7 cells (Figure 12A). The ratio between total and phosphorylated 
p38(MAPK) is greater in the MCF-7 cell line compared to the MB-231 cell line (Figure 12B). 
The hypothesis states that a functional interaction between the p38(MAPK) and MAO-A 
systems alters breast cancer cells in an ER-dependent manner. In glial cells, MAO-A activity is 
inhibited by p38(MAPK) (198) and we expected to find a similar effect in breast cancer cells. If 
this pattern holds, then CLG and SB203580 should induce opposite effects within each assay 
since CLG is an irreversible inhibitor of MAO-A and SB203580 inhibits p38(MAPK). 
Additionally, inhibition of p38(MAPK) should prevent any inhibition of MAO-A by 
p38(MAPK) (Figure 5 in ‘Introduction’ section).We examined how p38(MAPK) inhibition 
(using SB203580) affected MAO-A activity in MCF-7 and MB-231 cells. 
  










Figure 12. Endogenous MAO-A and p38(MAPK) expression in MCF-7 versus MB-231 
cells. Using immunoblotting techniques, endogenous MAO-A protein (A) expression was higher 
in the MB-231 cells compared to MCF-7 cells. The ratio of total to phosphorylated p38(MAPK) 
protein expression (B) was greater in the MCF-7 cell line compared to the MB-231 cells.  
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3.1 Impact of p38(MAPK) inhibition on MAO-A enzymatic activity 
We determined the effects of CLG and SB203580 on the enzymatic activity of MAO-A 
in both MCF-7 and MB-231 cells. CLG (1 µM, 24 h) treatment decreased MAO-A activity in 
MB-231 cells [t = 22.27, df = 46, P < 0.0001] (Figure 13) as well as in MCF-7 cells [t = 37.65, 
df = 4, P < 0.0001] (Figure 13). In MB-231 cells treated with SB203580 (10 µM, 24 h), there 
was a decrease in MAO-A activity in comparison to the activity observed in the vehicle control 
group [t = 3.39, df = 6, P = 0.0148] (Figure 14). In MCF-7 cells, SB203580 (10 µM, 24 h), as 
expected, increased MAO-A activity [t = 4.82, df = 6, P = 0.0029] (Figure 14).  
The effect of p38(MAPK) inhibition was not consistent in both cell lines. This indicates a 
priori that while p38(MAPK) could influence MAO-A in these cells lines, the mechanisms 
involved were not the same. In addition, this assay demonstrated that the innate activity of 
MAO-A in the MB-231 cells was very high compared to that in the MCF-7 cells. These data 
supported the use of these two cell lines for comparison in this study. 
 
3.2 The effects of overexpression and inhibition of MAO-A and inhibition of 
p38(MAPK) on mitochondrial function 
To determine whether the two inhibitors, i.e. CLG and SB203580, exerted any effect on 
the general ‘health’ of the cells, we treated both cell lines with combinations of the inhibitors and 
measured the reduction of MTT to formazan crystals. Note that the MTT assay provides 
quantitative data regarding cell viability, proliferation, and/or mitochondrial function, but does 
not necessarily reveal specific cellular mechanisms.   
MTT conversion was used to evaluate mitochondrial function/cell viability in MB-231 
and MCF-7 cells after treatment with CLG (1 µM) and/or SB203580 (10 µM) for 24 hours. A 
reduction in MTT conversion was observed in MCF-7 cells treated with CLG and SB203580 
compared to the vehicle control group [F(3,23) = 7.441, P = 0.0016]. There was no effect of 
either inhibitor on MTT conversion in MB-231 cells [F(3,23) = 0.880, P = 0.4682] (Figure 15). 
 






Figure 13. MAO-A enzymatic activity in MB-231 and MCF-7 cells treated with clorgyline. 
MAO-A activity was significantly inhibited by CLG (1 µM, 24 h).  in both cell lines (n=3). ***: 
P < 0.0001 versus the respective vehicle (Veh)-treated control group. 
  







Figure 14. MAO-A enzymatic activity in MB-231 and MCF-7 cells treated with SB203580. 
Treatment of MB-231 cells with SB203580 (10 µM, 24 h) resulted in a reduction in MAO-A 
activity, whereas treatment of MCF-7 cells with SB203580 (10 µM, 24 h) resulted in an increase 
in MAO-A activity (n≥4). *: P <0.05 & **: P <0.01, versus the respective vehicle (Veh)-treated 
control group. 
 




Figure 15.  MTT conversion in MCF-7 and MB-231 cells treated with CLG and SB203580. 
Cells were treated with SB203580 (10 M, 24 h) and/or CLG (1 M, 24 h). (A) The effect of 
CLG on MTT conversion was not statistically significant in MCF-7, but SB203580 had a 
pronounced effect in these cells. (B) Neither inhibitor had an effect in MB-231 cells. *: P < 0.05 
& **: P < 0.01 versus vehicle (VEH)-treated control cells (n=6-9). 
A 
B 
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A previous M.Sc. student in our research group, Xia Cao, originally tested the effects of 
MAO-A overexpression on MTT conversion. The overexpressed MAO-A results could also help 
to explain the inhibitor effects on MTT conversion. There was no effect of MAO-A 
overexpression on MTT conversion in the MB-231 cultures [t = 1.945, df = 13, P = 0.0737], 
perhaps because these cells already have high innate MAO-A activity. In contrast, the 
overexpression of MAO-A in MCF-7 cells increased MTT conversion [t = 5.891, df = 13, P < 
0.0001] (Figure 16). This was an unanticipated observation as we observed that treatment of 
MCF-7 with SB203580 induced MAO-A activity (Figure 14) and inhibited MTT conversion 
(Figure 15), yet overexpression of MAO-A induced MTT conversion (Figure 16). As already 
indicated, MTT results are not specific to any single cellular event and could represent multiple 
events, with a predominant effect overshadowing minimal effects. It is also possible that an MTT 
result could represent the cumulative output of several unrelated mechanisms. Although the 
results of the MTT conversion assay were perplexing, they do confirm that the p38(MAPK) and 
MAO-A systems do influence cell function, that the two cell lines are indeed different, and, as 
such, that they represent valid models for comparing and contrasting the effects of p38(MAPK) 
and MAO-A inhibition in the context of breast cancer. We chose to next examine the role of 
p38(MAPK) and MAO-A on tumourigenic properties of these two cell lines. 
 
3.3 Impact of MAO-A and p38(MAPK) inhibition on proliferation rate 
The ability of a cell line to form tumours is critical in breast cancer progression; hence we 
chose to first determine if CLG and/or SB203580 were affecting cell proliferation. Two-way 
analysis of variance revealed that the proliferation (based on cytometer cell counts) of vehicle-
treated MCF-7 cells was significantly increased over the 6-day test period [F(3,56) = 412.5, P < 
0.0001]. There was a modest effect of treatment [F(4,56) = 3.688, P = 0.0171] and neither was 
the interaction between days X treatments [F(12,56) = 1.167]. A similar trend was seen for MB-
231 cells over the 6-day test period [F(3,56) = 942.2, P < 0.0001]. In contrast with MCF-7 cells, 
however, there was a significant effect of SB203580 or CLG on their own (both showed 
significantly reduced proliferation on day 6), but this was cancelled out in the combined 
treatment  group  [F(4,56) = 45.00, P < 0.0001]  and the  interaction between  days X treatments  







Figure 16. MTT conversion in MCF-7 and MB-231 cells overexpressing MAO-A. Compared 
to the empty vector (Vec), overexpression of wildtype (WT) MAO-A in MCF-7 cells 
significantly increased MTT conversion. There was no effect of MAO-A overexpression in MB-
231 cells. ***: P < 0.001 versus Vec-transfected control cells (n=6-9). 
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was also significant [F(12,56) = 47.69] (Figure 17). The growth curves clearly show differences 
in the cell lines’ response to manipulation of the p38(MAPK) and MAO-A systems. It is also 
clear that the effects of the individual inhibitors (and, by extension, the individual systems) exert 
one effect when used independently, but the concurrent manipulation of both systems exerts an 
altogether novel effect. Clearly these systems do interact, but perhaps not in the way that was 
originally anticipated. The growth rates also do not corroborate the results of the MTT assay, 
which confirms the limitations of the interpretation of data generated by the MTT assay (i.e. in 
this case a one-day MTT assay is not necessarily a good indicator of what is transpiring within 
the cell). To confirm the validity of changes we observed in the growth rate assays, we chose to 
examine BrdU incorporation as another means of quantitating cell proliferation in these cell 
lines. 
Bromodeoxyuridine (BrdU) is a synthetic thymidine analog that is incorporated into a 
cell's DNA during cell division and is therefore a valid means of identifying proliferating cells 
(199). We did not observe any significant changes between the four treatment groups in either 
the MCF-7 [F(3,15) = 1.979, P = 0.1710] or MB-231 [F(3,11) = 0.4314, P = 0.7363] cell lines 
(Figure 18). Although this would initially suggest that neither the MAO-A or p38(MAPK) 
systems are significantly impacting proliferation rate, it should be borne in mind that these 
results were obtained over a 24 hour period (BrdU is toxic and is often only tested over short test 
periods). We are currently examining whether BrdU staining can be monitored over a longer test 
period (i.e. 96 and 144 h). At this point, we chose to examine how these two systems affected 
foci formation in the two cell lines. 
 
3.5 Absence of foci formation with MCF-7 and MB-231 cells 
We assayed for foci formation in order to assess to what extent contact-inhibited growth 
of MB-231 and MCF-7 breast tumour cells would be affected by treatment with CLG and/or 
SB203580. Under normal circumstances once cells have grown to full confluence, i.e. there is a 
monolayer of cells (referred to as 100% confluence), those cells that are ‘transformed’ (i.e.  that  
are  more tumour-like) will grow over each other to eventually form clumps of cells, or foci 
(200). Our  initial  attempt  was  not  successful  simply  due  to  technical   difficulties,   i.e.   the 





Figure 17. The growth rate of MCF-7 and MB-231 cells with p38(MAPK) and MAO-A 
inhibition. (A) Treatment with CLG and SB203580 did not exert a very profound effect in 
MCF-7 cells, (B) but the inhibitors on their own significantly inhibited the MB-231 growth rate. 
The growth rate of MB-231 cells treated with the combination of CLG+ SB203580 was not 
significantly different from the growth rate of vehicle (Veh)-treated MB-231 cells (n=4). 
A 
B 





Figure 18. BrdU incorporation in MCF-7 (A) and MB-231 (B) cells with CLG and 
SB203580. The cell lines were treated with CLG (1 µM) and SB203580 (10 µM) for 24 hours 
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monolayer lifted off of the plate during the wash step and the cells were subsequently lost, an 
improved technique was adopted to reduce lifting of the monolayer and also to improve the de-
staining step so that visualization of the foci would be easier. In our hands, MB-231and MCF-7 
cells did not form foci under any conditions even after a two week growth period. The results of 
this assay were not reproducible and inconclusive; therefore, the data has not been presented. 
Future attempts to perform this assay should follow the protocol outlined (‘Materials and 
Methods’ section), which was eventually developed, with the help of Jennifer Nyarko (Cancer 
Research Unit, Saskatoon), over several trial assays. We chose to use another approach to assess 
anchorage-independent growth, namely the soft agar assay.   
 
3.6 Effects on anchorage-independent growth following MAO-A and 
p38(MAPK) inhibition are restricted to the MB-231 cell line  
The formation of colonies in soft agar was used as a means of determining anchorage-
independent growth, another common sign of tumourigenicity. 
While we expected, based on the MTT results (Figure 15, above), that the inhibitors 
should have a more significant effect in the MCF-7 cell line, this was not what was observed 
[F(3,35) = 1.384, P = 0.2656]. In contrast, although we expected no effect of the inhibitors in 
MB-231 cells (based on the MTT assay), we actually observed a significant reduction in the 
growth of MB-231 colonies in soft agar with both inhibitors, either alone or in combination 
[F(3,27) = 5.000, P = 0.0078] (Figure 19). The reduced colony formation in MB-231 cells 
treated with either CLG or SB203580 suggested that the cells were less inclined to form tumours 
under these treatment conditions. This could be indicating that these cells are being directed to a 
phenotype that is less tumourigenic. In support of this notion, the literature reports that one of the 
reasons that the MB-231 cell line is often studied is because it is a metastatic cell line (201, 202). 
At this point, the inhibitors appear to have a more significant effect on the MB-231 cells; 
however, tumour formation (soft agar assay) and rapid cell growth (growth curves) are decreased 
during MAO-A and p38(MAPK) inhibition. Tumour cells typically  exhibit  these  characteristics 
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Figure 19. Anchorage-independent growth in MCF-7 and MB-231 cells with CLG and 
SB203580. (A) Whereas, colony formation in the MCF-7 cell line did not differ significantly 
between treatment groups or in comparison to the vehicle control group (VEH), (B) SB203580 
and CLG significantly reduced anchorage-independent growth of MB-231 cells. *: P < 0.05 
versus VEH-treated cultures. Mean colony count for MCF-7 cells (12±3 colonies, n=8) versus 
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Tumour cells typically exhibit these characteristics (soft agar colony formation and rapid 
growth), and tumour progression would be indicated by an increase in these parameters.  This is 
clearly not the case and suggests that perhaps we should examine these two cells lines based on 
their metastatic potential rather than simply on their ER status, this concept will be further 
discussed (‘Discussion’ section). Metastatic cells are more likely to migrate and invade 
surrounding tissue. We conducted a series of assays to assess the influence of the p38(MAPK) 
and MAO-A systems on the migratory and invasive potential of both cell lines. 
3.7 Migration & Invasion Assays 
3.7.1 Migration Assay 
Cell migration is based on chemotaxis, e.g. the movement along a chemical concentration 
gradient (203); chemotaxis of tumour cells is very important for tumour cells to disperse during 
metastasis (203). This assay was based on the number of cells that pass through a porous 
membrane; in this case we used the in vitro Transwell insert system (Figure 9A). The lower 
chamber contained 1 mL of DMEM supplemented with 10% FBS (chemoattractant); this volume 
allowed for contact with the underside of the Transwell insert (porous membrane) and 
established a concentration gradient between the upper and lower chamber. Each experiment 
included, as a control, a parallel set of Transwell inserts that contained 0.1% FBS in DMEM in 
the lower chamber. Of note, passive diffusion of cells through the filter membrane does not 
occur readily because pores of the filter are smaller than the size of the breast cancer cells. The 
MB-231 and MCF-7 cells normally display entirely different morphologies; however this is not 
apparent once they have migrated (Figure 20A) as all cells typically have a slightly altered 
appearance and exhibit an irregular shape following migration. 
The MB-231 cells are a more aggressive lineage and therefore showed a higher rate of 
migration in comparison to the MCF-7 cells. Migration rates were not significantly different 
between treatment groups of the MCF-7 cells [F(3,11) = 0.1399, P = 0.9333]. Of note, however, 
the MB-231 cells that received the MAO-A-inhibitor (independently  or  in  combination)  did  
display statistically significant increased migration (Figure 20B). The inhibition of p38(MAPK) 
had only a partial effect on migration in the MB-231 cells. Furthermore, when SB was used in 
combination with CLG the effect on migration was not additive. Taken together with the reduced  














Figure 20. Migration of MCF-7 and MB-231 cells treated with CLG and/or SB203580. (A) 
Representative images of migrating MB-231 and MCF-7 cells (preceding page). The cells are a 
purple shade; the small black spots are pores in the filter. (B) Cell migration was quantified and 
expressed as # of cells migrating with treatment over # cells in (VEH)-treated control group. Top 
panel: the inhibitor treatments had no effect on the migration of MCF-7 cells. Bottom panel: the 
inhibition of MAO-A (1 µM; 20h) and p38(MAPK) (10 µM; 20h) resulted in increased 
migration in MB-231 cells, but the effect was greatest with CLG treatment. P<0.01 versus 
vehicle VEH-treated group (n=3, in triplicate).  
B 
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colony formation in treated MB-231 cells observed from the soft agar assay, the increased 
migration seen in treated groups reflects a tendency towards an increased metastatic potential in 
this cell line in response to the drug treatments. To further investigate the metastatic potential of 
these cell lines following treatment, we examined models of cell invasion through various 
physiological barriers, i.e models of the endothelial cells of the vasculature and the basement 
membrane. 
3.7.2 Invasion through a monolayer of EA.hy926 cells (model of the vasculature) 
In order to assess the ability of MCF-7 and MB-231 cells to undergo intra/extravasation, 
we wanted to determine their ability to migrate through, or invade, a layer of endothelial cells 
(EA.hy926) before migrating through a Transwell chamber filter (the filter acts as a platform for 
counting cells). Our initial attempt did not provide any conclusive result as we suspected that 
some of the EA.hy926 cells were migrating through the filter along with the breast cancer cells. 
In order to test this hypothesis, we assayed the migration of EA.hy926 cells in the absence of 
breast cancer cells and, unfortunately, determined that there was migration of these cells in 
response to the chemoattractant (Figure 21). In retrospect this is not surprising as the literature 
identifies EA.hy926 cells as a hybrid cell line between human endothelial-like cells derived by 
fusing human umbilical vein endothelial cells and human lung adenocarcinoma cells (A549 
cells) (204). These cancer-endothelial hybrids (EA.hy926) have been used to examine 
mechanisms of cancer metastasis and invasion (205) and a recent report by Lu and colleagues 
(205) indicated that EA.hy926 cells had a greater migratory potential than the parental A549 
cells, which are highly metastatic epithelial lung cancer cells. 
Several alternative approaches were examined. We thought that EA.hy926 cells could be 
differentiated from MB-231 and MCF-7 cells based on their morphology, but this proved invalid 
as all cells were irregular and elongated following migration. We also attempted to identify cell 
types based on their differential expression of specific proteins, i.e. E-cadherin and vimentin 
(based on concurrent studies being done with these proteins; see section ‘Immunocytochemistry’ 
on page 74). Unfortunately, MB-231 and EA.hy926 cells both express high levels of vimentin 
and low levels of E-cadherin. The MCF-7 cells did not display sufficient migratory capacity in 
this assay; as such they were not included in this investigation. We are currently using MB-231 
cells that stably express the green fluorescent protein (GFP)  (a  gift  from Dr. Andrew Freywald,  











Figure 21. EA.hy926 cell migration using Transwell chambers. Each of the invasion 
chambers were seeded with 5x10
5
 EA.hy926 cells and cells migrating onto the lower surface of 
the filter were stained using hematoxylin. These are representative images of migrated EA.hy926 
cells following a 96-hour incubation period (top panel) with a chemotactic concentration (10%) 
of FBS and (bottom panel) without; i.e. 0.5% FBS. 
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Biochemistry, University of Saskatchewan) and we will use this fluorescent marker to 
differentiate the MB-231 cells from any migrated EA.hy926 cells. 
3.7.3 Invasion through matrigel (model of the basement membrane) 
The protocol for the invasion assay using matrigel (an artificial matrix that is used to 
model the extracellular matrix) is dependent on the cell lines being investigated. Because of the 
variability in the rates of invasion, it was necessary to determine the optimal conditions for each 
cell line. Several trials and control experiments were conducted using a range of matrigel 
concentrations (2 mg/mL vs. 1 mg/mL), matrigel volumes (25 µL, 50 µL, 75 µL or 100 µL) and 
the test period for the migration itself (24, 48 or 72 hours). Once the optimal conditions were 
established (e.g. 50 µl of 1 mg/mL matrigel, with a 72 hour invasion period), the effects of CLG 
and SB203580 on the invasive capacity of MB-231 cells was assessed. 
Treatment of MB-231 cells with SB203580 and CLG, either alone or in combination, 
induced an increase of 50% in the invasive capacity for these cells, although the variability in the 
data rendered the increase not statistically significant [F(3,15) = 2.821, P = 0.0839] (Figure 22). 
The tendency for an increase in invasiveness in the cells treated with the inhibitors is expected 
given that active migration of tumour cells (as seen in Figure 20) is a prerequisite for tumour-cell 
invasion. 
Given the metastatic nature of MB-231 cells, the observed increases in migration and 
invasion strongly suggest an effect beyond the behaviour expected if it were acting as a primary 
site tumour cell line. It is important to understand that ER(-) cells are still very capable of 
forming tumours, but the MB-231 cells were not giving any indication of exhibiting tumour-like 
characteristics during p38(MAPK) or MAO-A inhibition. At this point, we started to consider 
that the metastatic potential of this cell line is playing a role in the cell’s reaction to SB203580 
and CLG, rather than its actual ER status. If these drugs are exerting an influence that is more 
dependent on the cell’s metastatic status, then we would expect changes in proteins including E- 
cadherin and vimentin which are associated more with phenotypes beyond the primary tumour 
stage. 
 







Figure 22. Invasiveness of MB-231 cells treated with CLG and SB203580. Although the 
treatments resulted in an increased invasiveness of the MB-231 cells, this was not statistically 
significant (n = 4). 
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3.8 Immunocytochemistry 
The expression of intercellular junction and membrane cytoskeletal proteins has been 
extensively investigated in the context of cancer progression (206). Mechanisms contributing to 
invasive and metastatic potential may involve alterations in such proteins as E-cadherin, 
vimentin and β-catenin. The expression of E-cadherin and vimentin in MB-231 and MCF-7 cells, 
in the absence of MAO-A and/or p38(MAPK) activity, was evaluated using 
immunocytochemistry. 
The distribution patterns of E-cadherin and vimentin were different between the two cell 
lines. The expression of vimentin was modest and appeared to be restricted to specific patterns 
within MCF-7 cells and its expression did not appear to be altered following any of the 
treatments with inhibitors (Figure 23). In these same cells, E-cadherin was segregated in areas of 
cell-cell contact and was significantly up regulated by treatment with SB203580 or CLG, either 
alone or in combination (Figure 23). We confirmed the expression of vimentin in MB-231 cells 
(207) and demonstrated that it was clearly localized to the plasma membrane (and allowed for 
imaging of the cell body and extensions). As with MCF-7 cells none of the treatments had any 
overt effect on vimentin expression in MB-231 cells. In contrast, MB-231 cells, which are 
known to be E-cadherin null (208), responded quite uncharacteristically to the inhibitor 
treatments by a modest induction of E-cadherin expression (Figure 24). 
The distribution of protein expression in both MCF-7 and MB-231 cell lines was confirmed 
using quantitative analysis of the images using densitometry techniques. The image processing 
software, ImageJ, produces densitometric data which can then be graphically represented. The 
line profile plot method creates a graphical representation of pixel intensities based on a 
bisecting line centre of the nucleus (‘50’) and extending beyond the edge of the cell (‘0’ on the x-
axis) (see Figure 25 for an example). In the MCF-7 cells, vimentin is concentrated around the 
nucleus (i.e. the line on the graph is higher nearer the ‘50’). E-cadherin expression in these same 
cells is more in proximity with the plasma membrane (between ‘30-40’) (Figure 26A). 
The changes in protein expression observed using immunocytochemistry results were 
confirmed by western blot analysis (Figure 27). These  results  indicate a  reduction  of  vimentin    
























Figure 23. Vimentin and E-cadherin expression in MCF-7 cells treated with CLG and 
SB203580. Immunofluoresecence was used to detect vimentin and E-cadherin expression in 































Figure 24. Vimentin and E-cadherin expression in MB-231 cells treated with CLG and 
SB203580. Immunofluoresecence was used to detect vimentin and E-cadherin expression in MB-















Figure 25. An example of a bisecting line centered on the nucleus. Using ImageJ one can 
produce a two-dimensional graph of the intensities of pixels along a line drawn within an image. 
This is illustrated using an image of an MCF-7 cell and using immunocytochemical techniques to 
quantitate the distribution of E-cadherin expression.  The line starts outside of the cell (‘0’) and 
terminates in the centre of the nucleus (‘50’). 
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protein expression in the CLG+SB203580 group of MCF-7 and a rise in vimentin in the group 
treated only with SB203580. In these same cells, there was an increase in E-cadherin cleavage 
following drug treatment as seen by the appearance of the stronger lower bands in the 55-65 kDa 
range (Figure 27). In MB-231 cells, vimentin was reduced in the SB203580-treated group 
(Figure 27), thus confirming the results of our densitometric analyses (Figure 28). As expected, 
E-cadherin expression was not detectable in the vehicle-treated control MB-231 cells, but was 
induced by SB-203580 treatment (with or without CLG); the latter observation confirmed our 
densitometric analyses. 
The epithelial-to-mesenchymal transition (EMT) is now acknowledged for its central role 
in tumour progression (169). E-cadherin is also a critical switch during EMT in early embryonic 
development during which time downregulation of E-cadherin results in the acquisition of a 
fibroblastic phenotype causing dissociation from the parent epithelium and subsequent migration 
(163). This re-organization of the epithelial structure (209, 210) and the loss of adhesion between 
epithelial tumour cells can reflect a loss of E-cadherin expression in the plasma membrane (211).  
A closer look at our immunocytochemistry results (Figure 24) and the corresponding 
densitometry (Figure 28) suggests that this newly expressed E-cadherin in MB-231 cells is 
closely associated with the nucleus. To confirm this notion, we undertook nuclear fractionation 
studies in combination with western blot analysis. 
 
3.9 E-cadherin expression in cytosolic versus nuclear subcellular fractions 
The fractionation studies confirm the increase in E-cadherin expression in the cytosol of 
SB203580-treated MCF-7 cells and also reveal a doublet at 130 kDa in the nuclear extract 
(soluble fraction of the nucleus). The top band of the doublet disappears with SB203580 
treatment and the bottom band appears stronger, although we did not quantify this (Figure 29A). 
In these same fractions we looked for the expression of GSK3, a protein which, when phospho-
inhibited, stimulates the transcription of Slug and Snail (repressors of E-cadherin expression) and 
ultimately induces EMT (212). A similar pattern, i.e. increased E-cadherin concurrent with the 
detection of a phospho-GSK3β immunodetectable band was also evident in MB-231 cell cytosol 




Figure 26. Quantification of E-cadherin and Vimentin localization in treated MCF-7 cells. 
The distribution E-cadherin (A) and vimentin (B) in MCF-7 cells treated with CLG (1 µM) 
and/or SB203580 (10 µM) for 96 hours determined through densitometric analysis of images 
(using ImageJ) obtained using immunofluorescence. The data points are based on a line starting 
outside of the cell (‘0’ on the x-axis) and terminating at the centre of the nucleus (‘50’). 
A
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Figure 27.  Western blots of E-cadherin and vimentin expression in MCF-7 and MB-231 
cells with CLG and SB203580. The expression of vimentin (58 kDa) and E-cadherin (estimated 
135 kDa) in cell lysate of MCF-7 cells was increased (with the exception of vimentin in 
CLG+SB203580 cultures). In contrast, the expression of vimentin was unchanged in MB-231 
lysates regardless of treatment, but the expression of E-cadherin was detectable in lysates from 
cells treated with SB203580 (either alone or in combination with CLG). 
  




Figure 28. Quantification of E-cadherin and Vimentin localization in treated MB-231 cells. 
The distribution E-cadherin and vimentin in MB-231 cells treated with CLG (1 µM) and/or 
SB203580 (10 µM) for 96 hours determined through densitometric analysis of images obtained 
using immunofluorescence. Details as in Figure 22. 
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Figure 29. E-cadherin expression in nuclear and cytosolic fractions of MCF-7 and MB-231 
cells (previous page). (A) E-cadherin (estimated 135 kDa) and phospho-GSK3 (p-GSK3) (47 
kDa) expression was monitored in the cytosolic and nuclear extracts of treated MCF-7 cells. 
Note the appearance of E-cadherin in the cytosolic fractions and the loss of the upper band in the 
doublet in the nuclear matrix of SB203580 (SB)-treated cells. Levels of p-GSK3β are increased 
in corresponding cytosolic fractions. (B)  E-cadherin and p-GSK3 expressions were monitored 
in the cytosolic and nuclear extracts of treated MB-231 cells. Note the appearance of E-cadherin 
in the cytosolic fractions of CLG- and/or SB203580 (SB)-treated cells. Levels of p-GSK3 are 
increased in corresponding cytosolic fractions. (C) An immunodetectable E-cadherin band at 130 
kDa appears to associate with the nuclear matrix in MCF-7 cells (insoluble fraction). There was 
no detectable E-cadherin in corresponding fractions from treated MB-231 cells. (kDa/kiloDalton: 
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(there was no detectable E-cadherin signal in corresponding nuclear extracts) (Figure 29B). We 
did observe differences in the cleavage pattern of E-cadherin (exists as a 135 kDa inactive 
precursor protein (213) and in its mature form as a 120-124 kDa protein (214)). Subcellular 
fractionation revealed that the band lost from the E-cadherin doublet in MCF-7 cells appears to 
be associated with the nuclear matrix (insoluble fraction) (Figure 29C). We are currently unclear 
as to the relevance of this observation. -Catenin levels were not significantly affected by 
treatment in either of the two cell lines (Figure 30). 
3.10 Cross-linking Studies 
MCF-7 and MB-231 cells were examined for MAO-A expression and it was revealed that 
MAO-A expression in MCF-7 is predominantly perinuclear, whereas the expression of MAO-A 
is more diffuse in MB-231 cells. In addition, a portion of this MAO-A is associated with the cell 
membrane (Figure 31A). Parallel cultures were harvested and aliquoted to different 1.7 mL 
Eppendorf tubes. These cell suspensions were then treated with either DSS (disuccinimidyl 
suberate: a non-cleavable and membrane permeable cross-linker) or BS
3
 
(bis(sulfosuccinimidyl)suberate: a non-cleavable and membrane impermeable cross-linker). 
Proteins were then extracted and resolved for standard western blot analysis and probed for 
MAO-A (Figure 31B). The results of this experiment confirmed that MAO-A exists in different 
pools. In MCF-7 cells, the reduced MAO-A levels that are expressed are primarily intracellular. 
In contrast, in MB-231 cells, there is a significant pool of MAO-A that  appears in a higher 
molecular weight complex following treatment with BS
3
, which confirms (given that BS
3
 is cell 
impermeable) that the MAO-A must be associated with the plasma membrane. This was 
confirmed by a reduction in MAO-A activity in similarly treated cell homogenates (Figure 31C) 
and suggests that the role of MAO-A in cancer cell progression might be more complex than 


















Figure 30. Western blot of β-catenin protein expression in treated MB-231 and MCF-7 
cells. Cell lysate of CLG- and/or SB203580 (SB)-treated MCF-7 and MB-231 cells were probed 
for the expression of β-catenin (92 kDa). There were no significant effects of any treatment in 
either cell line. 
  




























Figure 31. MAO-A in MCF-7 and MB-231 cells with immunofluorescence and 
immunoblotting. Multiple pools of MAO-A exist in MCF-7 and MB-231 cells. (A) 
Immunofluorescence confirms that the levels of expression of MAO-A protein in MCF-7 and 
MB-231 cells corresponds to the differences in innate activities determined above (see Figure 9).  
While the MAO-A in MCF-7 cells appears to concentrate in the perinuclear region 
(mitochondria and endoplasmic reticulum), in MB-231 cells MAO-A expression is more diffuse 
and is also associated with the plasma membrane. (B) Cross-linking studies with DSS (a cell-
permeable cross-linking reagent) and BS
3
 (a cell impermeable reagent) reveals a very strong 
band in BS
3
-treated homogenates, suggesting that at least a portion of MAO-A is expressed on 
the cell membrane. (C) A reduction in MAO-A activity confirmed MAO-A crosslinking in BS
3
-
treated homogenates of both MCF-7 and MB-231 cells. 
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4 DISCUSSION 
The MCF-7 cell line is a well-characterized ER(+) cell line that is weakly invasive, while 
the MB-231 cell line is ER(-) and highly invasive (215) and incurs a post-epithelial-
mesenchymal transition (post-EMT) classification (216). These two breast cancer cell lines 
exhibit very different phenotypes making them ideal candidates for comparison, thus providing a 
means of understanding what might be occurring in diverse cell populations. We chose to study 
the MCF-7 and MB-231 breast cancer cell lines so as to align with other studies and reports that 
often compare and contrast the two.   
The current study sought to investigate if a functional interaction between the 
p38(MAPK) and MAO-A systems exists in breast cancer cells. This working hypothesis was 
based on the conclusion drawn from previous work from our laboratory that p38(MAPK) 
directly inhibits MAO-A (148). This was an unanticipated conclusion as the activation of both 
MAO-A, as an H2O2-generating enzyme, and p38(MAPK), as a ‘stress-associated’ kinase, is 
most often associated with an apoptotic phenotype. Others, however, have reported on the 
constitutive activation of p38(MAPK) in brain, which suggests a role for this kinase in normal 
physiology (217, 218). Ultimately, we determined that the Serine209 residue in MAO-A was a 
target for p38(MAPK) and that the inhibition of MAO-A by transient p38(MAPK) activation 
was a pro-survival event that permitted the cell to survive a minor or transient toxic event. In 
contrast, prolonged activation of p38(MAPK) would initiate cell death cascades, as expected of 
this pro-apoptotic kinase (219). During a review of the literature we found a report of significant 
losses of MAO-A status [e.g. mRNA] in 95% (!) of human cancers (19), particularly in pre-
cancerous states. These authors proposed that the loss of MAO-A status (and the possible 
increase in serotonin that would follow the loss of this catabolic enzyme) could indicate 
progression towards cancer. Thus, the loss of MAO-A status could be a useful biomarker and 
could be a powerful means for testing for the potential onset of cancer. 
Breast cancer is one of the most prevalent malignancies in woman. The expression of 
receptors for female hormones, particularly estrogen, is currently used as a defining feature in 
breast cancers. Indeed, it is now generally acknowledged that approximately 60% of 
premenopausal and 75% of postmenopausal women with breast cancer have an estrogen receptor 
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positive [ER(+)] subtype (220). In addition, the approximate 30% prevalence of mood disorders, 
particularly depression, in breast cancer patients is two to three times greater than that in the 
general population (221, 222). This suggests a role for MAO-A (given its clear link to 
depression) in breast cancer, as does the report that the use of antidepressants, including MAO 
inhibitors, can increase the risk of breast cancer (223, 224). Furthermore, the loss of MAO-A 
status in breast cancer cells could explain why MAOIs diminish the effects of cisplatin and 
irradiation therapy in tumour cells compared to normal non-tumourigenic cells (225). In contrast, 
others have found that increased MAO-A activity is linked to malignancy (at least 
experimentally) (226), while inhibition of MAO has been linked to a better prognosis in prostate 
(227) and colorectal (228) cancers. The evidence for a link between the use of newer-generation 
antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs) (which do not target 
MAO), prior to (223, 229) or after (230) diagnosis and breast cancer recurrence is also 
ambivalent. Needless to say, the literature is inconclusive regarding the role of MAO-A in 
cancer, but this provides an opportunity for new research, such as our own, to elucidate the topic.  
Our interest was piqued further by the observation that tamoxifen, a selective estrogen 
receptor modulator used in both pre- and postmenopausal women with ER(+) breast cancer (231, 
232), has also been linked to MAO-A (220) as well as with a significant risk for developing 
depression (233, 234). As stated above, MAO-A function is regulated, in part, by the 
p38(MAPK) pathway. Our work as well as that of others based on observations in CNS-derived 
cell lines strongly suggests that the effect of p38(MAPK) on MAO-A is cell line-dependent, with 
potential contribution by both transcription-dependent and -independent mechanisms (148, 198, 
235-237). Interestingly, resveratrol, a polyphenolic compound isolated from red grapes, is a 
potent MAO-A inhibitor (238) that induces p38(MAPK)-dependent (239) and p38(MAPK)-
independent (240) cell death in the ER(+) MCF-7 cell line and in the ER(-) MDA-MB-231 cell 
line, respectively. The role of p38(MAPK) in cell growth, invasive potential and a tamoxifen-
resistant phenotype is clear in MCF-7 cells (118, 241-243). Interestingly, to further relate 
tamoxifen, p38(MAPK) and MAO-A, the expression of MAO-A has long been known to be 
tightly regulated by the estrogen [receptor] system (244, 245). The regulation of MAO-A by 
estrogen is tissue-specific; for instance in the brain estrogen decreases MAO-A (246). This is 
consistent with the effects of estrogen-replacement therapy, which decreases MAO-A to increase 
available 5HT, associated with improvements in mood (247). 
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As there has not been any single characterization of the roles of both p38(MAPK) and 
MAO-A in these cell lines, we chose to compare and contrast the influence of these two systems 
on breast cancer cell tumourigenicity. To do this we used two pharmacological inhibitors that are 
known to be specific for p38(MAPK) and MAO-A, namely SB203580 and clorgyline (CLG), 
respectively. We found that the innate levels of MAO-A activity in the two cell lines differed, 
with MB-231 cells having a high level of MAO-A activity and MCF-7 cells having a 
significantly lower level of MAO-A activity. We also confirmed the inhibitory potential of the 
MAO-A inhibitor CLG in these cell lines. Given the previous work from our laboratory (148), 
we expected that the inhibition of p38(MAPK) would increase MAO-A activity. While the 
results using the MCF-7 cells supported this notion, the effect of SB203580 in MB-231 cells did 
not. Furthermore, both SB203580 and CLG had a negative effect on MTT conversion in MCF-7 
cells. While the effect of CLG on MCF-7 cells was corroborated by an increase in MTT 
conversion following the ectopic expression of MAO-A protein, the effects of SB203580 and 
CLG in either cell line were not corroborative of our proposed model. In other words, if 
SB203580 was inhibiting p38(MAPK) and activating MAO-A in MCF-7 cells (as hypothesized), 
then why would it exert a similar effect as an MAO-A inhibitor on MTT conversion? Clearly, the 
interaction between p38(MAPK) and MAO-A function was cell line-dependent. Yet, the fact that 
tamoxifen is known to exert an effect on MAO-A (220) and is effective against ER(+) cells, such 
as the MCF-7 cell line (248), suggests that the effects of MAO-A would be important in ER(+) 
cells, our data do not support this hypothesis. In fact our data suggest that the cell's ER status 
might not be the primary factor that dictates whether it is influenced by MAO-A-dependent 
mechanisms. Thus, it was clear that the cell’s phenotype, if influenced by these two 
proteins/enzymes, was not going to simply rely on an interaction between the two proteins and 
the regulation of MAO-A catalytic activity.  
One possibility for these inconsistent findings could be a limitation of the MTT 
conversion assay. This assay is thought to reflect mitochondrial metabolic rate and is a widely 
accepted technique employed to indirectly reflect viable cell counts (249, 250). Yet, while it 
represents a simple, inexpensive and efficient method, it may not be entirely accurate given that 
metabolic activity can be altered by different conditions and chemical treatments and, thus, 
introduces considerable variation in the results reported from such assays (251). Since the key 
processes differentiating cancer cells from normal cells is their ability to divide indefinitely, to 
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form a malignant tumour and to invade other tissues (84, 86), we undertook several other assays 
designed to study specific aspects of  breast cancer cell function and tumourigenicity.  
We determined that MB-231 cells grew in soft agar much more readily than MCF-7 cells, 
therefore cell-line dependent effects of the inhibitors were once again observed. Indeed, the 
inhibitors decreased MB-231 cell growth in soft agar, but had no effect on MCF-7 cells in this 
assay. Given the ability of SB203580 and CLG to reduce the growth rate of MB-231 cells and 
the ability of these inhibitors to also reduce growth on soft agar, this could be indicating that 
these cells are adopting a migratory phenotype. In support of this change in phenotype, we 
demonstrated that treated MB-231 cells were more likely to migrate (e.g. through a Transwell 
filter) and showed a more invasive phenotype, i.e. by migrating through matrigel (used as a 
model of the basement membrane). It is known that anchorage-dependent cell growth is a 
mechanism that guards against metastasis. Of all the cells that are shed by tumours and capable 
of migrating and invading the circulation, only those few that are not restricted by anchorage-
dependent growth can re-establish at secondary sites and metastasize (252). The MB-231 cell 
line is frequently studied as a representative metastatic cell line (201, 202) and is designated as a 
post-EMT cell line (207, 216) which suggests a state characterized by a loss of adhesion and 
increased cell mobility (165).  
As we had already questioned whether the ER status of the MCF-7 cell line was a factor 
in the roles of p38(MAPK) and MAO-A, it is quite possible that what we were observing were 
phenotypic changes that were more so dependent on the cell’s metastatic potential. With this in 
mind, we chose to examine these cells for the levels of expression of E-cadherin and vimentin, 
two markers which have been extensively implicated in the induction of EMT. A reduction in E-
cadherin levels and an increase in vimentin expression are distinct features of the EMT and the 
reverse is true during the MET (152). Using both immunofluorescence and western blot analysis, 
we observed a significant increase in E-cadherin expression in both cell lines following treatment 
with the p38(MAPK) and/or the MAO-A inhibitors. While this might prevent the metastatic 
conversion of epithelial cells during cancer progression, in cells which have already undergone 
the transition, such as MB-231 cells (post-EMT), the atypical expression of E-cadherin could be 
indicative of the MET. During the end stages of metastasis the MET would lead to the 
establishment of micrometastases at the secondary site (158, 253).  
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Mechanistically, the presence of E-cadherin in the E-cadherin-null MB-231 cell line 
(254) could be due to changes in GSK3β signalling. E-cadherin is integral to the maintenance of 
the epithelial state and its expression is suppressed by the Snail protein (255), a transcriptional 
regulator in cancer development (256). The non-phosphorylated form of GSK3β prevents the 
action of Snail (255), thereby indirectly regulating E-cadherin expression. E-cadherin is 
synthesized as a 135 kDa inactive precursor protein (213) and the mature form of E-cadherin is a 
120-124 kDa protein (214). Proteolytic cleavage of full-length E-cadherin at a site adjacent to the 
transmembrane domain releases an extracellular N-terminal fragment (80 kDa) (257) that has 
been implicated in the induction of cancer cell invasion (258, 259).  In addition, when E-cadherin 
is cleaved by the γ-secretase complex the resulting cytosolic C-terminal fragment 2 (E-
cad/CTF2) can translocate to the nucleus (260), which supports another potential pathway for 
increased motility in metastatic cells. The translocation of E-cadherin to the nucleus has also 
been shown to be of paramount importance for pituitary adenoma tumour invasion (261). While 
the phospho-inhibition of GSK3 would be expected to repress E-cadherin, this was not the case 
under our experimental conditions. However, it would appear that the post-translational 
regulation of E-cadherin could depend on a GSK3-dependent event. In addition, the E-cadherin 
processing (or, perhaps more importantly, its subcellular localization rather than its expression 
levels) might have more impact in our treated cell lines. The multiple band pattern that was 
apparent on the films may correlate with the multiple species of E-cadherin mentioned 
throughout the literature. The mechanism which mediates E-cadherin cleavage in these breast 
cancer cell lines requires further investigation.  The nuclear fractionation also revealed that the 
band lost from the E-cadherin doublet in MCF-7 cells appears to be associated with the nuclear 
matrix (insoluble fraction) (Figure 24, bottom panel), however, we are unclear of the importance, 
or lack thereof, of this observation. 
While it is still unclear exactly how the p38(MAPK) and MAO-A systems are exerting 
their effects in these two cell lines, it is becoming clear that these two systems are potentially 
playing a very specific and apparently very subtle role during a specific window in the metastatic 
process. According to the molecular and phenotypic changes in these cells under the current 
laboratory conditions, they appear to be in an invasive/migratory state in preparation for 
establishing tumour growth. According to Kalluri and Weinberg (165), the MB-231 cells in our 
study are exhibiting an intermediate phenotype which manifests during the EMT/MET transition. 
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If we extrapolate from the molecular and cellular analyses of EMT/MET features outlined by 
Blick and colleagues (254), these events would be best placed in the extravasation step of 
metastasis. 
While p38(MAPK) inhibitors do not form part of the normal battery of 
chemotherapeutics associated with breast cancer in the clinic, antidepressants do. Clearly they 
are not used to treat the breast cancer per se, but secondary or reactive depression (to a diagnosis 
of breast cancer) is a serious issue in this patient population. Since most antidepressants used 
currently fall primarily into the class of drugs known as selective serotonin reuptake inhibitors 
(SSRIs), whose mechanism of action, as the name implies, involves the blockade of the reuptake 
(clearance) of serotonin from the synaptic cleft, MAO-A might not be a significant 
consideration. However, the one SSRI which is contraindicated in breast cancer is paroxetine 
(262). Studies suggest that the increase in death associated with this drug in the breast cancer 
population is due to its ability to inhibit CYP2D6-mediated activation of tamoxifen, thereby 
mitigating its therapeutic effect (100). Yet preliminary in vitro investigations using purified 
human MAO-A indicates that paroxetine is also a relatively potent MAO-A inhibitor (A. Holt, 
G.B. Baker & D.D. Mousseau, unpublished data). Therefore, if MAO-A inhibition is having 
significant effects at the secondary site, as our results suggests, then this could have serious 
clinical implications. During early stage breast cancer the antidepressants may not have a 
detectable effect, i.e. at stages when tumour cells resemble the MCF-7 cell line. However, if 
antidepressants are administered in the later stages when the cancer has metastasized (and more 
so resemble MB-231 cells), then the drugs might trigger MET in circulating tumour cells and 
indirectly promote the establishment of the tumour cell at a secondary location in the body.  
On a final note, as part of our ongoing characterization of MAO-A and in the hope of 
understanding why MAO-A could be exerting such distinct effects in these two cell types, we 
determined where MAO-A was being expressed within the cell as there is quite a substantial 
literature that indicates that it is not expressed exclusively on the outer mitochondrial membrane. 
Using immunocytochemistry, we confirmed that MCF-7 cells express low levels of MAO-A and 
that the MAO-A appears to be localized to the perinuclear region, where most of the 
mitochondria would be found. In contrast, MB-231 cells express much higher levels of MAO-A, 
which is in keeping with the higher levels of innate MAO-A activity in this cell line. However, 
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we also observed that the distribution of MAO-A is much more diffuse and that a portion of the 
MAO-A signal seems to be associated with the plasma membrane. This is not unexpected as 
some of the older literature shows clear evidence of a plasma membrane-associated pool of 
MAO in various tissues (263). We confirmed the expression of MAO-A on the plasma 
membrane by cross-linking studies using a cell impermeable amine-amine cross-linking reagent 
that would clearly only cross-link those proteins exposed to the outside of the cell. BS
3 
is the 
hydrophilic analog of DSS at the same concentration (1 mM) the crosslinking reagents yielded 
different results which supports our findings that BS
3 
is a membrane impermeable reagent that is 
interacting with MAO-A. While we did detect a modest high molecular weight band (on western 
blot) in the MCF-7 cell line, suggesting that a minor pool of MAO-A is expressed on the plasma 
membrane, parallel studies using the MB-231 cell line revealed a very strong high molecular 
weight band. In parallel cultures, MAO-A activity was decreased following similar cross-linking 
studies, which would be expected of a protein that is exposed on the outside of the cell and 
inactivated by irreversible cross-linking of amine groups. 
Perhaps these distinct pools of MAO-A contribute to different cellular events and it is 
only the cumulative effects of all MAO-A-mediated events that is detectable as a phenotype. For 
example, a generalized decrease in mao-A mRNA is observed in most cancers (19), yet MAO-A 
activity is increased in experimental breast cancer in rats (226) and paradoxical increases in 5-
HT (which would not be the anticipated consequence of increased MAO-A availability) in 
human breast cancer are thought to support tumour growth (264). Similarly, MAO-A protein is 
clearly induced in prostate cancer (227), yet, again paradoxically, serotonin is concurrently 
increased in this cancer (265) to the point that it is also proposed as a valid marker for tumour 
progression (266). This clearly suggests that the MAO-A protein, while present in the cell, does 
not necessarily promote a phenotype that is based strictly on the catalytic activity of the MAO-A 
protein. Again, subtle and, as yet, unclear mechanisms are clearly implicated.  
While it is clear that the p38(MAPK) and MAO-A systems do interact in these cell lines, 
it is clear that they do not interact in the manner that was hypothesized (based on our previous 
work using neuronal and glial cell lines). In addition, while some of the effects observed in this 
study may have been modest, it is quite possible that their effect(s) in vivo would be very subtle 
and would accumulate and become more pronounced after long-term MAO-A inhibition. This is 
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important because medications being used to alleviate depressive symptoms are meant to alter 
conditions within the brain; however these substances are delivered systemically and their effects 
may be induced on other cell types as well. The effects of the substance could be the same as in 
neuronal cells, opposite or entirely novel and unknown. As a result, it is important to recognize 
that treatment with antidepressants not only alter brain function but also influence the entire 
system. 
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5 PROSPECTIVE INVESTIGATIONS 
Another approach may be to perform similar tumour and invasion assays using a catalytic 
dead species of MAO-A so as to provide another level of potential differentiation. It is possible 
that MAO-A function may extend to effect cellular processes independent of its catalytic activity 
as our recent studies have suggested. We hope to better understand MAO-A function by building 
on current crosslinking studies to confirm our present findings. It would also be very interesting 
to examine more fully the mechanisms and pathways involved in the context of MAO-A and 
p38(MAPK) in breast cancer and determine the upstream activators and downstream targets 
involved. This study may further benefit from the use of more clinically relevant antidepressants, 
namely moclobemide (reversible MAO-A inhibitor) and newer-generation SSRIs, such as 
fluoxetine (Prozac) to treat cells and determine effects of these drugs on cell phenotype, viability, 
etc. and what role MAO-A has in these phenotypes. 
It is also our intention to conduct in vivo studies to understand some ambiguities that 
have surfaced from in vitro results. We have recently obtained an MB-231 cell line that stably 
expresses the green fluorescent protein (GFP). This will allow for visual identification of MB-
231 cells following their injection into nude mice. Nude mice are often used for the study of 
tumourigenicity as they are immunocompromised and, thus, do not ‘reject’ foreign transplanted 
tissues such as human breast cancer cells. Properties such as tumour growth (measurement of 
tumour size) and metastatic potential (appearance of secondary tumours in, for example, lungs) 
will be monitored using the MB-231-GFP cells in both vehicle-treated control mice and 
antidepressant-treated mice. In addition, the strategy to target MAO-A with both acute and 
chronic drug treatments will provide an advantage in clarifying how MAO-A modulating drugs 
may be influencing breast cancer prognosis. Moreover, it is reasonable to anticipate that these 
results could facilitate future investigations in understanding the role of p38(MAPK) and MAO-
A in the tamoxifen-resistance profile in breast cancers. 
Our results indicate clear differences between MCF 7 (ER+) and MB-231 (ER-) breast 
cancer cell lines in response to shifting levels of MAO-A and p38(MAPK), which could have 
significant bearing on breast cancer cell prognosis. Our in vitro findings strongly suggest that the 
influence of MAO-A on cell phenotype is less dependent on the respective cell's ER status and 
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perhaps more so dependent on the cell's metastatic potential. If this is the case, then the 
contribution of MAO-A to [clinical] metastatic breast cancer should be duly considered when 
considering an antidepressant drug treatment for depression in this (and other) cancer patient 
population. 
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